



(12) **DEMANDE DE BREVET CANADIEN**
CANADIAN PATENT APPLICATION

(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2018/10/24
(87) Date publication PCT/PCT Publication Date: 2019/05/02
(85) Entrée phase nationale/National Entry: 2020/04/24
(86) N° demande PCT/PCT Application No.: EP 2018/079197
(87) N° publication PCT/PCT Publication No.: 2019/081595
(30) Priorité/Priority: 2017/10/25 (EP17198420.6)

(51) Cl.Int./Int.Cl. *C07K 16/40*(2006.01),
A61K 39/00 (2006.01), *A61P 9/04* (2006.01)
(71) Demandeur/Applicant:
4TEEN4 PHARMACEUTICALS GMBH, DE
(72) Inventeur/Inventor:
BERGMANN, ANDREAS, DE
(74) Agent: MARKS & CLERK

(54) Titre : LIANT DPP3 DIRIGE VERS ET SE LIANT A DES EPITOPE DPP3 SPECIFIQUES ET SON UTILISATION
DANS LA PREVENTION OU LE TRAITEMENT DE MALADIES/ETATS AIGUS ASSOCIES AU STRESS OXYDATIF
(54) Title: DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE
PREVENTION OR TREATMENT OF DISEASES / ACUTE CONDITIONS THAT ARE ASSOCIATED WITH
OXIDATIVE STRESS

(57) Abrégé/Abstract:

The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization

International Bureau



(10) International Publication Number

WO 2019/081595 A4

(43) International Publication Date
02 May 2019 (02.05.2019)(51) International Patent Classification:
C07K 16/40 (2006.01) A61P 9/04 (2006.01)
A61K 39/00 (2006.01) (88) Date of publication of the international search report:
20 June 2019 (20.06.2019)(21) International Application Number:
PCT/EP2018/079197Date of publication of the amended claims:
06 September 2019 (06.09.2019)(22) International Filing Date:
24 October 2018 (24.10.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
17198420.6 25 October 2017 (25.10.2017) EP(71) Applicant: SPHINGOTEC THERAPEUTICS GMBH
[DE/DE]; Neuendorfstrasse 15A, 16761 Hennigsdorf (DE).(72) Inventor: BERGMANN, Andreas; Am Rosenanger 78,
13465 Berlin (DE).(74) Agent: BOEHMERT & BOEHMERT; Dr. Ute Kilger,
Hollerallee 32, 28209 Bremen (DE).(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with amended claims (Art. 19(1))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: DPP3 BINDER DIRECTED TO AND BINDING TO SPECIFIC DPP3-EPITOPES AND ITS USE IN THE PREVENTION
OR TREATMENT OF DISEASES / ACUTE CONDITIONS THAT ARE ASSOCIATED WITH OXIDATIVE STRESS

(57) Abstract: The present invention provides binder directed to and binding to a DPP3 protein or functional derivative thereof and its use in a method of prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress. With this context, specifically the present invention provides a binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

WO 2019/081595 A4

DPP3 binder directed to and binding to specific DPP3-epitopes and its use in the prevention or treatment of diseases / acute conditions that are associated with oxidative stress

5 FIELD OF THE INVENTION

In a first major aspect of the invention, subject matter of the invention is a binder being directed to and binding to a dipeptidyl peptidase 3 (DPP3) protein or functional derivative thereof.

10 In another embodiment of the first major aspect of the invention, the aforementioned binder is provided for the use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress.

15 In another embodiment of the first major aspect of the invention, the aforementioned binder is provided for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress, and wherein said diseases are selected from a group comprising neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, 20 inflammation, sepsis, septic shock and SIRS.

In a second major aspect of the present invention, a binder is provided that is directed to and binding to an epitope according to SEQ ID NO.: 2, and wherein said binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2, and wherein the epitope is 25 comprised in DPP3 as depicted in SEQ ID NO.: 1.

The below text refers to the above second major aspect of the invention:

Additional subject matter of the invention is the aforementioned binder being directed to and 30 binding to an epitope according to SEQ ID NO.: 2, wherein said binder is directed to and binding to an epitope according to SEQ ID NO.: 3, and wherein said binder recognizes and binds to at least three amino acids of SEQ ID NO.: 3, and wherein the epitope is comprised in DPP3 as depicted in SEQ ID NO.: 1.

Additional subject matter of the invention is the aforementioned binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said binder is directed to and binding to an epitope according to SEQ ID NO.: 4, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 4, and wherein the epitope is comprised in DPP3 as depicted in SEQ ID NO.: 1..

5 Additional subject matter of the invention is the aforementioned binder being directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said binder is selected from a group comprising an antibody or antibody fragment or non-Ig scaffold, and wherein the epitope is comprised in DPP3 as depicted in SEQ ID NO.: 1.

10 **In a third major aspect of the invention**, the above mentioned binder of the second major aspect of the invention that are directed to and binding to an epitope according to SEQ ID NO.: 2 is a dipeptidyl peptidase 3 (DPP3) binder directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

15 20 Additional subject matter of the invention is the aforementioned binder being directed to and binding to an epitope according to SEQ ID NO.: 2 according to the third aspect of the invention, wherein said binder is a monoclonal antibody or monoclonal antibody fragment, and wherein the complementarity determining regions (CDRs) in the heavy chain comprises the sequences:

25

SEQ ID NO.: 7, SEQ ID NO.: 8 and/ or SEQ ID NO.: 9

and the complementarity determining regions in the light chain comprises the sequences:

30 SEQ ID NO.: 10, KVS and/ or SEQ ID NO.: 11.

Additional subject matter of the invention is the aforementioned binder being directed to and binding to an epitope according to SEQ ID NO.: 2 according to the third aspect of the

invention, wherein said binder is a humanized monoclonal antibody or humanized monoclonal antibody fragment, wherein the heavy chain comprises the sequence:

SEQ ID NO.: 12

5

and wherein the light chain comprises the sequence:

SEQ ID NO.: 13.

10 Additional subject matter of the invention is anyone of the aforementioned binder being directed to and binding to an epitope according to SEQ ID NO.: 2 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress, and wherein the epitope is comprised in DPP3 as depicted in SEQ ID NO.: 1.

15

Specific subject matter of the present invention is a binder, specifically a dipeptidyl peptidase 3 (hereinafter DPP3) binder, directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids (aa), preferably at least 4 aa of SEQ ID NO.: 2.

20 Further subject matter of the present invention is a binder, specifically a DPP3 binder, directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids (aa), preferably at least 4 aa of SEQ ID NO.: 2, for use in the prevention or treatment of diseases or acute conditions of a patient, whereby said disease or acute condition is associated with oxidative stress.

25 Also, subject matter of the present invention is a binder, specifically an anti-DPP3 antibody or an anti-DPP3 antibody fragment, binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof or an anti-DPP3 non-Ig scaffold binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said anti-DPP3

antibody or anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold recognizes and binds to at least three amino acids (aa), preferably at least 4 aa of SEQ ID NO.: 2.

With the above context, also subject matter of the present invention is a binder in accordance

5 with the invention, specifically an anti-DPP3 antibody or an anti-DPP3 antibody fragment, binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof or an anti-DPP3 non-Ig scaffold binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said anti-DPP3 antibody or anti-DPP3 antibody
10 fragment or anti-DPP3 non-Ig scaffold recognizes and binds to at least three amino acids (aa), preferably at least 4 aa of SEQ ID NO.: 2, for use in the prevention or treatment of diseases or acute conditions of a patient, whereby said disease or acute condition is associated with oxidative stress.

15 Further subject matter of the present invention is a method of prevention or treatment of diseases or acute conditions of a patient, whereby said disease or acute condition is associated with oxidative stress, characterized in that a binder directed to and binding to DPP3, or a binder being directed to and binding to SEQ ID.: 2 as epitope that is comprised in DPP3 protein or a functional derivative thereof, or an anti-DPP3 antibody or an anti-DPP3 antibody

20 fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold being directed to and binding to SEQ ID.: 2 as epitope that is comprised in DPP3 protein or a functional derivative thereof is administered to said patient in pharmaceutically effective amounts.

Subject matter of the present invention is further a pharmaceutical composition comprising a

25 binder directed to and binding to DPP3, or a binder being directed to and binding to SEQ ID.: 2 as epitope that is comprised in DPP3 protein or a functional derivative thereof, or an anti-DPP3 antibody or an anti-DPP3 antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold being directed to and binding to SEQ ID.: 2 as epitope that is comprised in DPP3 protein or a functional derivative thereof for the use in the prevention or treatment of diseases
30 or acute conditions of a patient, whereby said disease or acute condition is associated with oxidative stress.

Another subject of the present invention is a pharmaceutical composition comprising a binder of the invention, or a DPP3 binder in accordance with the invention, specifically an anti-DPP3 antibody or an anti-DPP3 antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold binding to DPP3 for use in the prevention or treatment of diseases or acute conditions of a patient, whereby said disease or acute condition is associated with oxidative stress as described above, and wherein said pharmaceutical composition comprises at least one additional pharmaceutically active drug which e.g. may be used as primary medicament in methods of treatment of a disease or acute condition and wherein said treatment induces oxidative stress as side effect, and thus the said binder, or DPP3 binder, anti-DPP3 antibody or the anti-DPP3 antibody fragment binding to DPP3 or the anti-DPP3 non-Ig scaffold binding to DPP3 may act as secondary medicament, which reduces or regulates the said induced oxidative stress.

A further embodiment of the invention is a kit comprising a binder, or a DPP3 binder in accordance with the invention, specifically an anti-DPP3 antibody or an anti-DPP3 antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold binding to DPP3 for use in the prevention or treatment of diseases or acute conditions of a patient, whereby said disease or acute condition is associated with oxidative stress as described above, and wherein said pharmaceutical composition optionally comprises at least one additional pharmaceutically active drug which e.g. may be used as primary medicament in methods of treatment of a disease or acute condition and wherein said treatment induces oxidative stress as side effect, and thus the said DPP3 binder, anti-DPP3 antibody or the anti-DPP3 antibody fragment binding to DPP3 or the anti-DPP3 non-Ig scaffold binding to DPP3 may act as secondary medicament, which reduces or regulates the said induced oxidative stress.

25

Modulating anti-DPP3 antibody, fragment, scaffold

Moreover, subject matter of the present invention is a binder in accordance with the invention, or an anti-DPP3 antibody or an anti-DPP3 antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold binding to DPP3 as described above for the use as a medicament, wherein said binder, or antibody or said antibody fragment or said non-Ig scaffold is a modulating binder, antibody or fragment or scaffold.

In a preferred embodiment said modulating anti-DPP3 antibody or a modulating anti-DPP3 fragment or a modulating non-Ig scaffold is used in the prevention or treatment of diseases or an acute condition in a patient, whereby said disease or acute condition is associated with oxidative stress.

5

Further, in accordance with the invention, said modulating anti-DPP3 antibody or an anti-DPP3 antibody fragment or a modulating non-Ig scaffold of the invention regulates the bioactivity of DPP3.

10 With the context of the invention, DPP3 bioactivity may be defined as the DPP3 enzyme activity or the regulating activity of DPP3 in the oxidative stress pathway.

15 In accordance with the invention, said modulating anti-DPP3 antibody or an anti-DPP3 antibody fragment or modulating non-Ig scaffold of the invention may enhance the bioactivity of DPP3.

In another embodiment of the invention, said modulating anti-DPP3 antibody or an anti-DPP3 antibody fragment or modulating non-Ig scaffold of the invention may reduce the bioactivity of DPP3.

20

In another specific embodiment with the context of the present invention, a “modulating” anti-DPP3 antibody or a modulating anti-DPP3 antibody fragment or a modulating non-Ig scaffold as described above is an anti-DPP3 antibody or an anti-DPP3 antibody fragment or a modulating anti-DPP3 non-Ig scaffold blocks the bioactivity of DPP3 at least 10 %, 25 preferably at least 50 %, more preferably > 50 %, most preferably 100%.

30 In a specific embodiment a modulating binder, or modulating anti-DPP3 antibody or a modulating anti-DPP3 antibody fragment or a modulating anti-DPP3 non-Ig scaffold according to the present invention is used for the prevention or treatment of diseases or an acute condition of a patient, wherein said disease or acute condition is associated with oxidative stress.

Another embodiment of the present invention is a kit or an assay comprising the above described binder, or anti-DDP3 antibody, and/or an anti-DPP3 antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold binding to DPP3 for use in the prevention or treatment of a disease or acute condition of a patient, whereby said disease or acute condition is
5 associated with oxidative stress.

BACKGROUND

Dipeptidyl peptidase 3 (DPP3)

10 Dipeptidyl peptidase 3 – also known as Dipeptidyl aminopeptidase III, Dipeptidyl arylamidase III, Dipeptidyl peptidase III, Enkephalinase B or red cell angiotensinase; short name: DPP3, or DPPIII – is a metallopeptidase that removes dipeptides from physiologically active peptides, such as enkephalins and angiotensins. Hereinafter, the expression “DPP3” will be used throughout the text as abbreviated form of the above described dipeptidyl
15 peptidase 3.

20 DPP3 was first identified and its activity measured in extracts of purified bovine anterior pituitary by Ellis & Nuenke, 1967. The enzyme, which is listed as EC 3.4.14.4, has a molecular mass of about 83 kDa and is highly conserved in prokaryotes and eukaryotes (Prajapati & Chauhan, 2011).

The amino acid sequence of the human variant of DPP3 is depicted in SEQ ID No.: 1. DPP3 is a mainly cytosolic peptidase, which is ubiquitously expressed. Despite lacking a signal sequence, a few studies reported membranous activity (Lee & Snyder, 1982).

25 DPP3 is a zinc-depending exo-peptidase belonging to the peptidase family M49. It has broad substrate specificity for oligopeptides from three or four to ten amino acids of various compositions and is also capable of cleaving after proline. DPP3 is known to hydrolyze dipeptides from the N-terminus of its substrates, including angiotensin II, III and IV; 30 angiotensin 1-7 (Cruz-Diaz et al., 2016); Leu- and Met-enkephalin; endomorphin 1 and 2. The metallopeptidase DPP3 has its activity optimum at pH 8.0 - 9.0 and can be activated by addition of divalent metal ions, such as Co^{2+} and Mg^{2+} . Structural analysis of DPP3 revealed the catalytic motifs HELLGH (hDPP3 450 - 455) and EECRAE (hDPP3 507 - 512), as well

as the following amino acids, that are important for substrate binding and hydrolysis: Glu 316, Tyr 318, Asp 366, Asn 391, Asn 394, His 568, Arg 572, Arg 577, Lys 666 and Arg 669 (Prajapati & Chauhan, 2011; Kumar et al., 2016; numbering refers to the sequence of human DPP3, see SEQ ID No.: 1). Considering all known amino acids or sequence regions that are involved in substrate binding and hydrolysis, the active site of human DPP3 can be defined as the region between amino acids 316 and 669.

Recent findings for DPP3 indicate its role for being a part of the protein metabolism but also playing a role in blood pressure regulation, pain modulation, inflammatory processes and oxidative stress regulation (Prajapati & Chauhan, 2011).

DPP3 has been also shown to be a promising biomarker in several publications. It has been shown that DPP3 activity is elevated in homogenates of ovarian and endometrial tumors. DPP3 activity even increases with the severity/malignancy of said tumors (Šimaga et al., 1998 and 2003). Immune histology and western blot analysis of glioblastoma cell lines also revealed elevated DPP3 levels (Singh et al., 2014).

DPP3 was also proposed to be a potential arterio-risk marker (US 2011008805) and as a marker for rheumatoid arthritis (US 2006177886). The patent application WO 2005/106486 describes DPP3-expression and activity as diagnostic marker and DPP3 as therapeutic target in all kinds of diseases, due to ubiquitous expression of DPP3 in or at surface of cell. EP 1498480 mentions the potential diagnostic and therapeutic use of hydrolytic enzymes, including DPP3.

The relevant prior art can be further summarized as follows:

WO 2005/106486 describes in a general manner a method of screening for therapeutic agents which may be useful in the treatment of diseases, comprising cardiovascular diseases, infections, respiratory diseases, cancer, endocrinological diseases, metabolic diseases, gastroenterological diseases, inflammation, haematological diseases, muscle skeleton diseases, neurological and urological diseases. In said method of screening, a test compound is contacted with a DPP3 polynucleotide and the binding between said test compound and said DPP3 polynucleotide is detected. Further, the document describes in a general manner

compounds, which may bind to and / or activate or inhibit the activity of DPP3. Further, the invention describes pharmaceutical compositions, which comprise such compounds.

5 Liu et al. 2007 describe a relation between activation of the antioxidant response element (ARE) and overexpression of DPP3 and Sequestome 1 in IMR-32 cells. Overexpression of DPP3 and Sequestome 1 stimulated the Nrf2 translocation and led to increased levels of NAD(P)H:quinone oxireductase 1, a protein which is transcriptionally regulated by the ARE.

10 Hast et al. 2013 describe a comparison of the spectrum of KEAP1 interacting proteins with the genomic profile of 178 squamous cell lung carcinomas characterized by The Cancer Genome Atlas and reveal amplification and mRNA over-expression of the DPP3 gene in tumors with high Nrf2activity but lacking Nrf2 stabilizing mutations. They further describe that tumor-derived mutations in KEAP1 are hypomorphic with respect to Nrf2 inhibition and that DPP3 over-expression in the presence of these mutants further promotes Nrf2 activation.

15

Overexpression of DPP3

Thus, according to the prior art, overexpression of intracellular DPP3 is known to be closely linked to oxidative stress regulation. DPP3 was identified as an activator of the antioxidant response element (ARE) in an unbiased screen of a cDNA library consisting of approximately 20 15,000 full-length human expression cDNAs (Liu et al. 2007).

25 DPP3 disrupt the KEAP1-Nrf2 complex by competing with Nrf2 about the KEAP1 binding site (Hast et al. 2013). This disruption prevents NRF2 degradation and subsequently leads to translocalization of Nrf2 into the nucleus and ARE activation. Overexpression of DPP3 in neuroblastoma cells (Liu et al. 2007), in HEK293T cells (Hast et al. 2013) or in MCF7 breast cancer cells (Lu et al. 2017) activates Nrf2-mediated transcription. Active and inactive variants of DPP3 were overexpressed in MCF7 cells and showed the same regulatory effect on oxidative stress (Lu et al. 2017). Hast et al. (2013) also showed a loss-of-function effect: silencing of DPP3 using specific siRNA Nrf2-mediated transcription was decreased down to levels of Nrf2-silencing.

30 Although DPP3 is known as an intracellular protein, DPP3 activity was detected in some bodily fluids as well: retroplacental serum (Shimamori et al. 1986), seminal plasma (Vanha-

Perttula et al. 1988) and CSF (Aoyagi et al. 1993). In CSF there were elevated DPP3 activity levels measured in patients suffering from Alzheimer's disease (AD, Aoyagi et al., 1993).

DPP3 is known for being expressed as membranous, intracellular or circulating DPP3.

5

DPP3 has been not only proposed as potential biomarker but also as potential therapeutic target due to its ability to cleave several bioactive peptides. Influenca A virus changes host DPP3 levels for own replication (cell culture studies, Meliopoulos et al. 2012). Enkephalin and/or angiotensin degrading enzymes in general, including DPP3, have a therapeutic potential as targets for treatment of pain, cardiovascular diseases (CVD) and cancer and the corresponding inhibitors as potential treatments of pain, mental illnesses and CVD (Khaket et al. 2012, Patel et al. 1993, Igic et al. 2007).

Inhibition of DPP3

15 The activity of DPP3 can be inhibited unspecifically by different general protease inhibitors (e.g. PMSF, TPCK), sulphydryl reagents (e.g. pHMB, DTNB) and metal chelators (EDTA, o-phenanthroline) (Abramić et al. 2000, EP 2949332).

20 DPP3 activity can be further inhibited specifically by different kinds of compounds: an endogenous DPP3-inhibitor is the peptide spinorphin. Several synthetic derivatives of spinorphin, e.g. tynorphin, have been produced and shown to inhibit DPP3 activity to varying extents (Yamamoto et al. 2000). Other published peptide inhibitors of DPP3 are propioxatin A and B (US 4804676) and propioxatin A analogues (Inaoka et al. 1988).

25 DPP3 can also be inhibited by small molecules such as fluostatins and benzimidazol derivatives. Fluostatins A and B are antibiotics produced in *Streptomyces* sp. TA-3391 that are non-toxic and strongly inhibit DPP3 activity. So far, 20 different derivatives of benzimidazol have been synthesized and published (Agić et al., 2007; Rastija et al., 2015), of which the two compounds 1' and 4' show the strongest inhibitory effect (Agić et al., 2007).
30 Several dipeptidyl hydroxamic acids have been shown to inhibit DPP3 activity as well (Cvitešić et al., 2016).

Oxidative stress

Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species (hereinafter ROS) / reactive nitrogen species (hereinafter RNS) and antioxidants in favour of excessive generation of free radicals. This process leads to the oxidation of biomolecules with consequent loss of its biological functions and/or homeostatic imbalances, 5 whose manifestation is the potential oxidative damage to cells and tissues. Accumulation of ROS / RNS can result in a number of deleterious effects such as lipid peroxidation, protein oxidation and DNA damage (including base damage and strand breaks). Further, some reactive oxidative species act as cellular messengers in redox signalling. Thus, oxidative stress can cause disruptions in normal mechanisms of cellular signalling.

10

“ROS” and “RNS” are the terms collectively describing free radicals and other non-radical reactive derivatives, which are also called oxidants. Radicals are less stable than non-radical species, although their reactivity is generally stronger. A molecule with one or more unpaired electron in its outer shell is called a free radical. Free radicals are formed from molecules via 15 the breakage of a chemical bond such that each fragment keeps one electron, by cleavage of a radical to give another radical and, also via redox reactions. Free radicals related to oxidative stress include hydroxyl (OH[•]), superoxide (O₂^{•-}), nitric oxide (NO[•]), nitrogen dioxide (NO₂[•]), peroxyl (ROO[•]) and lipid peroxyl (LOO[•]). Also, hydrogen peroxide (H₂O₂), ozone (O₃), singlet oxygen (¹O₂), hypochlorous acid (HOCl), nitrous acid (HNO₂), peroxy nitrite (ONOO⁻), dinitrogen trioxide (N₂O₃), lipid peroxide (LOOH), are not free radicals and 20 generally called oxidants, but can easily lead to free radical reactions in living organisms.

Formation of ROS and RNS can occur in the cells by two ways: enzymatic and non-enzymatic reactions. Enzymatic reactions generating free radicals include those involved in 25 the respiratory chain, the phagocytosis, the prostaglandin synthesis and the cytochrome P450 system. Free radicals can be produced from non-enzymatic reactions of oxygen with organic compounds as well as those initiated by ionizing radiations. The non-enzymatic process can also occur during oxidative phosphorylation (i.e. aerobic respiration) in the mitochondria. For a review see Pham-Huy et al. 2008. Int J Biomed Sci 4 (2): 89-96.

30

Diseases associated with oxidative stress

In view of the stated above and with the context of the present invention, oxidative stress is linked to a number of diseases, including but not limited to neurodegenerative diseases,

metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer and inflammation, and thus associated therewith.

5 According to the prior art, intracellular DPP3 is known to be closely linked to oxidative stress regulation. DPP3 was identified as an activator of the antioxidant response element (ARE) in an unbiased screen of a cDNA library consisting of approximately 15,000 full-length human expression cDNAs (Liu et al. 2007; see also above). ARE regulates the expression of a number of cytoprotective antioxidant enzymes and scavengers, contributing to endogenous 10 defence against oxidative stress. This antioxidant effect of DPP3 is due to the interference of DPP3 with the KEAP1-Nrf2 signalling pathway. Nrf2 is a transcription factor that controls the basal and induced expression of an array of antioxidant response element-dependent genes to regulate the physiological and pathophysiological outcomes of oxidant exposure. Under normal or unstressed conditions, Nrf2 is bound to Kelch like-ECH-associated protein 1 15 (KEAP1) via its ETGE and its DLG motif. Within this protein cluster Nrf2 is kept in the cytoplasm, quickly ubiquinated and degraded by proteasome. Under oxidative stress, Nrf2 is not degraded, but instead translocates to the nucleus where it binds to a DNA promoter and induces expression of an array of antioxidant response element (ARE)-dependent genes. A variety of chemicals, including phytochemicals and derivatives (CDDO, sulforaphane), 20 therapeutics (oltipraz, auranofin), environmental agents (paraquat, arsenic), and endogenous chemicals [NO, 15d-PGJ2, nitro-fatty acids, and 4-hydroxynonenal (4-HNE)], induce ARE genes through Nrf2 (Ma 2013).

BRIEF DESCRIPTION OF THE INVENTION

25 In view of the stated above, the inventors surprisingly and unexpectedly found that oxidative stress can be also reduced or regulated by a binder directed to and binding to a DPP3 protein or functional derivative thereof.

30 The inventors also found that oxidative stress can be also reduced or regulated by a binder directed to and binding to an epitope of SEQ ID NO.: 2, wherein the epitope is comprised in the DPP3 protein.

Moreover, the present inventors found a dipeptidyl peptidase 3 (hereinafter DPP3) binder directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids (aa), preferably at least 4 aa of SEQ ID

5 NO.: 2.

In the above context, the inventors specifically found that oxidative stress may be reduced or regulated by an anti-DPP3 antibody or an anti DPP3-antibody fragment directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a

10 DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids (aa), preferably at least 4 aa of SEQ ID NO.: 2 or an anti-DPP3 non-Ig scaffold directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids (aa), preferably

15 at least 4 aa of SEQ ID NO.: 2.

Thus, the present invention provides the herein disclosed binder, and anti-DPP3 antibody or an anti-DPP3 antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold binding to DPP3 for use in methods of the preventive treatment or treatment of diseases or acute

20 conditions of a patient, whereby said disease or acute condition is associated with oxidative stress.

Moreover, with the herein provided binder, DPP3 binder, and specifically the anti-DPP3 antibody, or anti DPP3-antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold binding to DPP3, the inventors have found binder to DPP3 which rapidly reduce or regulate

25 oxidative stress in cells of a mammal when determined by the methods of respective biomarker measurements as further set out below.

Another subject of the present invention is a pharmaceutical composition comprising the

30 binder of the invention, DPP3 binder of the invention, and specifically comprising the anti-DPP3 antibody or an anti-DPP3 antibody fragment binding to DPP3 or an anti-DPP3 non-Ig scaffold binding to DPP3 of the invention for use in methods of the prevention or treatment of

diseases or acute conditions of a patient, whereby said disease or acute condition is associated with oxidative stress.

Hence, the herein disclosed pharmaceutical compositions are also provided for use in the
5 prevention or treatment of symptoms, or syndromes, or pathological and acute conditions and
disease associated problems, which are mediated by oxidative stress.

Diseases associated with oxidative stress

As mentioned above, the occurrence of oxidative stress is linked to a number of diseases or
10 disorders, which in accordance of the invention include:

- neurodegenerative diseases, wherein said neurodegenerative diseases may be selected from a group comprising Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)),
15
- metabolic syndrome, wherein said metabolic syndrome may be selected from a group comprising insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes,
- cardiovascular disorders, wherein said cardiovascular disorders may be selected from a group comprising atherosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction,
20
- autoimmune diseases, wherein said autoimmune diseases may be selected from a group comprising rheumatoid arthritis, systemic lupus erythematosus,
- inflammatory lung diseases, wherein said inflammatory lung diseases may be selected from a group comprising COPD, asthma,
25
- kidney diseases wherein said kidney diseases may be selected from a group comprising renal toxicity (drug-induced kidney disease), acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD),
- liver diseases wherein said liver diseases may be selected from a group comprising hepatotoxicity, viral hepatitis, cirrhosis,
30
- digestive diseases wherein said digestive diseases may be selected from a group comprising inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease, gastritis, pancreatitis and peptic ulcer,

- viral infectious diseases wherein said viral infectious diseases may be selected from a group comprising blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus,
- cancer, wherein said cancer may be selected from a group comprising prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer,
- and inflammation, and
- sepsis, septic shock, and SIRS.

10 In view of the stated above and with the context of the present invention, a detailed list of diseases and their association with oxidative stress is depicted in Table 1 below:

Table 1: The association of oxidative stress with diseases in accordance with the invention

Disease group	Diseases	Reference
Neurodegenerative disorders	Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS)	Liu et al. 2017; Manoharan et al. 2016
	Multiple sclerosis (MS)	Adamczyk and Adamczyk-Sowa 2016
Metabolic Syndrome	Insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension	Hutcheson and Rocic 2012
	Diabetes	Pitocco et al. 2013; Ullah et al. 2016
Cardiovascular disorders	atherosclerosis, hypertension, heart failure, cardiovascular ischemia	Elahi et al. 2009
	heart failure	Tsutsui et al. 2011
	cerebral ischemic injury/ stroke	Chen et al. 2011
	myocardial infarction	Hori and Nishida 2009
Autoimmune disease	rheumatoid arthritis	Quiñonez-Flores et al. 2016
	systemic lupus erythematosus	Perl 2013
Inflammatory lung disease	COPD, asthma	Holguin 2013

Kidney disease	renal toxicity (drug-induced kidney disease)	Hosohata 2016; Naughton 2008
	acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD)	Sureshbabu et al. 2015
Liver diseases	Hepatotoxicity (drug-induced, alcohol-induced)	Li et al. 2015
	Viral Hepatitis	Ivanov et al. 2017
	Cirrhosis	Vairappan 2015
Digestive diseases	Inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease	Tian et al. 2017; Bhattacharyya et al. 2014
	Gastritis, Pancreatitis, Peptic ulcer	Bhattacharyya et al. 2014
	blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus(HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus	Pohanka 2013; Schwarz 1996
Cancer	general cancer	Sosa et al. 2013; Kruk and Aboul-Enein 2017
	prostate cancer	Khandrika et al. 2009
	breast cancer	Nourazarian et al. 2014
	lung cancer	Valavanidis et al. 2013
	colorectal cancer	Perse 2013
	bladder cancer	Sawicka et al. 2015
	ovarian, endometrial, cervical cancer	Saed et al. 2017
	skin cancer	Narendhirakannan 2013
	gastric cancer	Ma et al. 2013
	liver cancer	Wang et al. 2013
Inflammation / sepsis, septic shock, SIRS	sepsis	Kruk and Aboul-Enein 2017
		Kaymak et al. 2011

In more detail:

Oxidative stress is suspected to be important in **neurological and neurodegenerative disorders** including Amyotrophic lateral sclerosis (ALS), Parkinson's disease, Alzheimer's disease, Huntington's disease, Depression, Multiple sclerosis, tardive dyskinesia (TD), epilepsy and acute diseases of the central nervous system, such as spinal cord injuries and/or brain traumatic. The human brain is vulnerable to oxidative stress due to many facts such as (i) metabolism of catecholamines; (ii) decrease in antioxidants; (iii) presence of transition metals; (iv) occurrence of brain trauma/injury; and also (v) the brain is an organ that proportionally requires more oxygen and (vi) expresses low levels of antioxidant enzymes, which contribute to formation of ROS. As a consequence of redox unbalance in brain, one of the most affected structures is the lipid membrane (*Rao and Balachandran 2002. Nutritional Neuroscience 5: 291–309*). A common feature of these diseases is oxidative damage of neurons, which might be responsible for the dysfunction or death of neuronal cells that contributes to disease pathogenesis.

Alzheimer's disease (AD), the most prevalent neurodegenerative disorder, is characterized by the progressive deterioration of behaviour, cognition and functionality, which significantly impairs daily living activities. Numerous experimental and clinical studies have demonstrated that oxidative damage plays a key role in the loss of neurons and the progression to dementia in Alzheimer's disease. The production of β -amyloid (A β), a toxic peptide often found in Alzheimer's patients' brain, is due to oxidative stress and plays an important role in the neurodegenerative processes. In addition, A β proteins can directly initiate free radical formation via the activation of NADPH oxidase. Moreover, inflammation is responsible for increased expression of cytokines, ROS levels, and cellular toxicity, thereby exacerbating AD progression. For review see *Liu et al. 2017. Oxidative Medicine and Cellular Longevity 2525967; Manoharan et al. 2016. Oxid Med Cell Longev 8590578*.

Huntington's disease (HD) is a progressive neurodegenerative disease linked with unstable expansion of cytosine, adenine, guanine (CAG) repeats in the HTT gene. The expansion of CAG repeats within the exon1 of the HTT gene gives rise to a mutation that leads to the elongation of polyglutamine tract, resulting in an HTT protein product that is susceptible to aggregation. The mHTT aggregates are accumulated throughout the brain of the affected

individuals, which can interrupt protein quality control and transcription process. Those alterations are potentially responsible for the aberrant motor and cognitive problems in HD. Though oxidative damage is not much reported in the early stages of HD, it is proposed as one of the major mechanisms in HD as it progresses. Elevated oxidative stress plays a critical 5 role in the late stage of HD pathogenesis. Impairment in the electron transport chain and mitochondrial dysfunction are the major mechanisms involved in the ROS mediated etiopathogenesis of HD. Dysfunction in the oxidative phosphorylation components has been documented in the brain tissues of HD patients. HD patients showed an increased level of oxidative stress markers accompanied by a decrease in antioxidant status compared to healthy 10 subjects. For review see Liu et al. 2017. Oxidative Medicine and Cellular Longevity 2525967; Manoharan et al. 2016. Oxid Med Cell Longev 8590578.

Parkinson's disease (PD), the most common neurodegenerative disease of the elderly, is characterized by progressive loss of muscle control. PD is predominant at the 6th decade of 15 life and men are 1.5 to 2 times more likely to contract the disease than women. Head trauma, illness, or exposure to environmental toxins is identified as a risk factor. This neurodegenerative disorder is characterized by tremor, rigidity, bradykinesia, and impairment in balance. PD also causes cognitive, psychiatric, autonomic, and sensory disturbances. The pathology of PD is characterized by the gradual and selective loss of dopaminergic neurons in 20 the substantia nigra pars compacta. Imbalance in dopamine metabolism due to oxidative stress has been recognised as a contributor to this disease. The major pathological findings include the presence of Lewy bodies in the substantia nigra and loss of nerve cells in the portions of its ventral tier. Several studies have reported impaired respiratory chain and somatic mitochondrial DNA mutations in the brain of patients with PD, which suggests the extensive 25 role of oxidative metabolism in PD. Enhanced dopamine metabolism in the brain of patients with PD could account for the accumulation of toxic radicals such as hydroxyl in the brain. Iron accumulation in the neurons in the redox active form plays a crucial role in pathogenesis of this disease. Accumulation of iron has been reported in the substantia nigra in patients diagnosed with PD, which suggests the critical role of iron-induced lipid peroxidation in 30 pathogenesis of PD. A twofold increase in protein oxidation has been shown in the substantia nigra of PD patients compared to healthy subjects. Accumulation of hydroxyl radical due to lowered glutathione content in the brain has been reported in PD patients. Lowered activities of antioxidant enzymes and non-enzymatic antioxidants could be responsible for the

progression of PD. For review see *Liu et al. 2017. Oxidative Medicine and Cellular Longevity 2525967; Manoharan et al. 2016. Oxid Med Cell Longev 8590578.*

Amyotrophic lateral sclerosis (ALS) is characterized by progressive loss of motor neurons in the anterior horn of the spinal cord. It is classified as either familial or sporadic depending on whether there is a clearly defined, inherited genetic element. Sporadic ALS (sALS) typically emerges between 50 and 60 years old. The onset of sALS is unknown, and thus the identification of causal genes and environmental factors remains elusive. In familial ALS, about 20% of the cases resulted from mutations in SOD1. The functions of SOD1 are diverse and include scavenging excessive superoxide radical, modulating cellular respiration, energy metabolism, and posttranslational modification. SOD dysfunction leads to a loss of antioxidant capability. Moreover, increased levels of ROS and ROS-associated damage have been widely reported in ALS. Increased markers of ROS damage have been found in biofluids of patients with sporadic ALS as well as in post-mortem tissue. For review see *Liu et al. 2017. Oxidative Medicine and Cellular Longevity 2525967.*

Multiple sclerosis (MS) is a multifactorial disease of the central nervous system (CNS) in which both inflammatory and neurodegenerative processes occur simultaneously. In the course of the disease inflammation is decreased whereas the degeneration of the CNS progresses. The inflammatory component in MS is important not only due to axonal and neuronal loss but also due to the fact that it starts the degenerative cascade in the early stage of MS. The induction of the activation of microglia and mitochondrial dysfunction plays a particular role in inflammatory processes. Microglia activated by T-lymphocytes release proteolytic enzymes, cytokines, oxidative products, and free radicals. It is also important that mitochondrial dysfunction results in an increased production of reactive oxygen species (ROS), which is detrimental to neurons and glia. On the other hand, oxidative stress damages the mitochondria, which disrupts the transport of adenosine triphosphate along the axon, and consequently leads to neurodegeneration. Oxidative stress is associated with the dysregulation of axonal bioenergetics, cytokine-induced synaptic hyperexcitability, abnormal iron accumulation, and the oxidant/antioxidant balance. Markers of oxidative stress assessed in the serum, erythrocytes CSF, saliva, and urine may have diagnostic properties whereas antioxidants may have clinical application in the future. For review see *Adamczyk and Adamczyk-Sowa 2016. Oxidative Medicine and Cellular Longevity 1973834.*

Oxidative stress is related to **metabolic syndrome** and its individual component pathologies, e.g. obesity, insulin resistance, dyslipidemia, impaired glucose tolerance and high blood pressure. The metabolic syndrome was defined by the World Health Organization criteria

5 (Alberti and Zimmet 1998. Diabet Med. 15:539–553; World Health Organization. 1999. Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization) that require the presence of insulin resistance identified by one of the following: (1) type II diabetes; (2) impaired fasting glucose; (3) 10 impaired glucose tolerance or (4) for those with normal fasting glucose levels (< 110 mg/dL), glucose uptake below the lowest quartile for background population under investigation under hyperinsulemic, euglycemic conditions, AND two of the following: (1) blood pressure: \geq 140/90 mmHg; (2) dyslipidemia: triglycerides (TG): \geq 1.695 mmol/L and high-density lipoprotein cholesterol (HDL-C) \leq 0.9 mmol/L (male), \leq 1.0 mmol/L (female); (3) 15 central obesity: waist:hip ratio $>$ 0.90 (male); $>$ 0.85 (female), or body mass index $>$ 30 kg/m²; (4) microalbuminuria: urinary albumin excretion ratio \geq 20 μ g/min or albumin:creatinine ratio \geq 30 mg/g.

Increased oxidative stress has emerged as playing a central role in metabolic syndrome and its 20 component pathologies and may be a unifying factor in the progression of this disease. Moreover, oxidative stress has been identified as a major mechanism of micro- and macrovascular complications in the metabolic syndrome. For review see Hutcheson and Rocic 2012. Exp Diabetes Res. 2012:271028.

25 There is a bulk of evidence demonstrating that mitochondrial ROS (predominantly superoxide anion) overproduction is involved in **diabetes** and diabetic complications. It was suggested that glucose can directly stimulate ROS overproduction, and it was also shown that high glucose (HG) activates various enzymatic cascades in mitochondria, including activation of NADPH oxidase, uncoupling of NO synthases and stimulation of xanthine oxidase. Glycated 30 proteins can also be the promoters of ROS formation, thus suggesting that different sources may be responsible for ROS overproduction and oxidative stress in diabetes. For review see Pitocco et al. 2013. Int. J. Mol. Sci. 2013, 14, 21525-21550.

Moreover, oxidative stress plays an important role in the pathogenesis and development of **cardiovascular diseases**, including hypertension, dyslipidemia, atherosclerosis, myocardial infarction, angina pectoris, and heart failure (*Elahi et al. 2009. Oxidative Medicine and Cellular Longevity 2(5): 259-269*). One of the key concepts of free radical mediated 5 pathogenesis of cardiovascular disease is endothelial dysfunction, whereby the regulation of vascular wall microenvironment is disrupted. ROS activity in the vessel wall, for example, is thought to contribute to the formation of oxidized LDL, a major contributor to the pathogenesis of atherosclerosis. Oxidative stress also plays a role in the ischemic cascade due to oxygen reperfusion injury following hypoxia. This cascade includes both **stroke** (*Chen et 10 al. 2011. Antioxidants and Redox Signaling 14(8): 1505-1517*) and **myocardial infarction (MI)** (*Hori and Nishida et al. 2009. Cardiovascular Research 81: 457-464*). During brain 15 ischemia/reperfusion, multiple detrimental processes take place, including overproduction of oxidants, inactivation of detoxification systems, and consumption of antioxidants. These changes cause the disruption of the normal antioxidative defense ability of brain tissue (*Chen et al. 2011. Antioxidants and Redox Signaling 14(8): 1505-1517*). For further review see 15 *Elahi et al. 2009. Oxidative Medicine and Cellular Longevity 2(5): 259-269*.

A number of experimental and clinical studies have demonstrated the increased generation of 20 ROS in **heart failure (HF)** and showed that oxidative stress is involved in the pathophysiology of HF in the heart as well as in the skeletal muscle. The high metabolic activity of the mitochondria-rich myocardium makes these findings seem intuitively obvious. 25 Oxidative stress clearly activates processes in isolated heart cells such as changes in gene expression and cell death that are now accepted components of myocardial remodeling and heart failure. Moreover, many studies have been performed in animal models that demonstrate therapeutic effects of antioxidants on progression of heart failure. For review see *Tsutsui et al. 2011. Am J Physiol Heart Circ Physiol 301: H2181-H2190*.

Excessive oxidative stress is thought to have an important role in the pathogenesis of 30 **autoimmune diseases**. Many studies have shown that T and B lymphocytes contribute to the pathogenesis of autoimmune diseases by the production of autoantibodies and ROS under environmental and genetic influence. Oxidative stress has been implicated in autoimmune disorders (**rheumatoid arthritis, systemic lupus erythematosus, psoriasis, and celiac disease**) where it plays an important role in the disease process. Oxidative stress is increased

in **systemic lupus erythematosus (SLE)**, and it contributes to immune system dysregulation, abnormal activation and processing of cell-death signals, autoantibody production and fatal comorbidities. Mitochondrial dysfunction in T cells promotes the release of highly diffusible inflammatory lipid hydroperoxides, which spread oxidative stress to other intracellular 5 organelles and through the bloodstream. Oxidative modification of self antigens triggers autoimmunity, and the degree of such modification of serum proteins shows striking correlation with disease activity and organ damage in SLE (*Perl 2013. Nat Rev Rheumatol. 9(11): 674–686*). **Rheumatoid arthritis (RA)** is an autoimmune disease characterized by chronic inflammation of the joints and tissue around the joints with infiltration of 10 macrophages and activated T cells. The pathogenesis of this disease is due to the generation of ROS and RNS at the site of inflammation. RA is one of the conditions that induce oxidative stress. A fivefold increase in mitochondrial ROS production in whole blood and monocytes of RA patients—compared with healthy subjects suggests that oxidative stress is a pathogenic hallmark in RA. Free radicals are indirectly implicated in joint damage because 15 they also play an important role as secondary messengers in inflammatory and immunological cellular response in RA. T-cell exposure to increased oxidative stress becomes refractory to several stimuli including those for growth and death and may perpetuate the abnormal immune response. On the other hand, free radicals can degrade directly the joint cartilage, attacking its proteoglycan and inhibiting its synthesis (for review see *Quiñonez-Flores et al. 2016. Biomed Res Int. 2016:6097417*).

There is now substantial evidence that **inflammatory lung diseases** such as asthma and chronic obstructive pulmonary disease (COPD) are characterized by systemic and local 25 chronic inflammation and oxidative stress. An important source for increased airway oxidative stress is the recruitment of inflammatory cells into the airway after exposure to trigger factors. These activated cells can generate anion superoxide through reduced nicotinamide adenine dinucleotide phosphate (NADPH) oxidase pathway. Mitochondrial dysfunction in airway epithelial cells, which occurs in response to mechanical and environmental stimuli, can also contribute to the formation of anion superoxide and airway 30 oxidative stress. Subjects with asthma have greater systemic and airway increased oxidative stress, which is associated with worse asthma severity. As with asthma, subjects with COPD have increased airway oxidative stress and nitrosative stress. Patients with COPD have a greater degree of immunostaining for nitrotyrosine in the airway epithelium and inflammatory

cells in sputumA significant imbalance in the airway thiol metabolism has also been described for patients with COPD, which may be associated with downstream redox transcription changes and proinflammatory events. For review see *Holguin 2013. Ann Am Thorac Soc 10 Supplement: S150–S157.*

5

Inflammatory bowel disease (IBD) is an incurable chronic inflammatory intestinal disorder of the gastrointestinal (GI) tract that dramatically impacts quality of life. Crohn's disease (CD) and ulcerative colitis (UC) are the principal types of IBD. CD may occur in any region of the GI tract involving the ileum and colon in a discontinuous pattern by transmural inflammation, while UC affects only the colon and rectum continuously and is restricted to the mucosa. Accumulating data from both experimental models and clinical studies indicate that oxidative stress signalling is involved in and contributes to the development of IBD through multiple levels of function. Oxidative stress leads to damages of the mucosal layer in the GI tract and bacterial invasion, which in turn stimulates the immune response and initiates IBD. During inflammation, immune cells, such as leukocytes, monocytes, and neutrophils augment ROS production during respiratory, prostaglandin, and leukotriene metabolism, resulting in further tissue damages. For review see *Tian et al. 2017. Oxid Med Cell Longev 4535194.*

20 **Celiac disease (CD)** is an immune-mediated chronic inflammatory disorder of the upper small intestine induced by gluten and related prolamines in genetically susceptible individuals. As in other autoimmune conditions, environmental, genetic, and immunological factors may be involved in the pathogenesis of CD. In addition to this, oxidative stress is also implicated in the pathogenesis of CD. For example, activation of xanthine oxidase is one of 25 the mechanisms of ROS overproduction in small intestinal mucosa of celiac patients. For review see *Patlevic et al. 2016. Integr Med Res 5: 250–258.*

30 **Gastritis** is defined as inflammation of the stomach mucosal lining and occurs in several conditions including *H. pylori* infection, NSAID use, alcohol consumption, and stress. **Peptic ulcer disease (PUD)** occurs in the proximal GI tract and is often associated with chronic gastritis. Gastric and duodenal ulcers represent the most common and chronic PUDs. Gastritis and peptic ulcer are caused by multiple factors, both endogenous and exogenous, and free radicals are closely linked to both conditions. There are several factors contributing to the

accumulation of ROS in the stomach. Reduced antioxidant enzyme SOD levels and antioxidant vitamin intake contribute to the accumulation of ROS associated with gastroduodenal inflammatory diseases. Ethanol-induced gastric inflammation is associated with increased superoxide generation. Phagocytic leukocytes are the main source of ROS in 5 chronic inflammation such as one observes in *H. pylori* induced gastritis and IBD. Significant numbers of neutrophils and/or macrophages infiltrate the gastric mucosa during inflammation, generating large amounts of ROS. For review see *Bhattacharyya et al. 2014. Physiol Rev 94: 329–354.*

10 Oxidative stress also plays a critical role in **liver diseases** like viral Hepatitis (Type A, B and C) and liver cirrhosis. It has been clearly established that **hepatitis C** is associated with strong oxidative stress. This was revealed in liver tissues and in blood serum/plasma samples of Cchronic hepatitis C patients using a variety of techniques, including direct measurement of ROS, quantification of DNA, lipid and protein oxidation products, as well as by assessing the 15 total oxidant/antioxidant status or the levels of individual antioxidants. Screening of the liver biopsies of chronic hepatitis C virus carriers revealed significant elevation of the levels of oxygen radicals and stress markers malondialdehyde (MDA) and 4-hydroxynonenal- (HNE)- and other protein adducts. In addition, serum/plasma of such patients is characterized by increased levels of a wide array of oxidative stress markers such as MDA, lipid peroxides, 20 protein carbonyl content or thioredoxin (for review see *Ivanov et al. 2017. Oncotarget, 2017, Vol. 8, (No. 3), pp: 3895-3932*).

Patients with chronic **hepatitis B** exhibit signs of pronounced oxidative stress. Levels of oxygen radicals in liver specimens from these patients exceed the levels in healthy people. 25 Patients with hepatitis B exhibit signs of oxidative stress not only in the liver but also in plasma/sera. Chronic hepatitis B is accompanied by an increase in total oxidant status and a concomitant reduction of total antioxidant status. Plasma/serum of these patients was also characterized by the elevated levels of ROS, including H₂O₂, and oxidation products of lipids and proteins. Oxidative stress is not just a hallmark of chronic HBV infection and advanced 30 liver disease; it is also observed in acute and occult hepatitis B, as well as in asymptomatic HBV infections. Occult hepatitis B infection is characterized by increased levels of ROS in lymphocytes and consequent DNA damage. However, the most dramatic changes have been

described in hepatitis B patients with **liver cirrhosis** and with acute chronic hepatitis B **liver failure** (for review see *Ivanov et al. 2017. Oncotarget. 2017, Vol. 8, (No. 3), pp: 3895-3932*).

Cirrhosis is a complication of many forms of chronic liver diseases and is a late stage of fibrosis, in which regenerative nodular formation surrounded by fibrous bands of the liver. In 5 cirrhosis, oxidative stress induced mainly by an overproduction of reactive oxygen species, which is a critical determinant of endothelial dysfunction and is due to disturbed balance between oxidant and antioxidant enzymes. Increased superoxide formation in the presence of equimolar concentrations of NO will lead to the formation of the potent ROS and reactive nitrogen species. For review see *Vairappan 2015. World J Hepatol 27; 7(3): 443-459*.

10

Hepatotoxicity implies chemical-driven liver damage. Drug-induced liver injury is a cause of acute and chronic liver disease. Drug-induced liver injury is responsible for 5% of all hospital admissions and 50% of all acute liver failures. The liver is the most frequently targeted organ in terms of drug toxicity. The production of radical species, specifically ROS and RNS, has 15 been proposed as an early event of drugs hepatotoxicity and as an indicator of hepatotoxic potential. It has been discovered that a lot of drugs could induce oxidative stress including increase of cellular oxidants and lipid peroxidation, depletion of antioxidants in the liver, such as anti-inflammation drugs, anti-analgesic drugs, anti-cancer drugs and antidepressants (*Li et al. 2015. Int. J. Mol. Sci. 16: 26087–26124*). More than 900 drugs have been implicated in 20 causing liver injury, which are hereby incorporated by reference (<https://livertox.nlm.nih.gov/>; *Björnsson 2016. Int. J. Mol. Sci. 17: 224*).

In the pathogenesis of **alcoholic liver disease (ALD)**, the direct consequence of ethanol metabolism also seems to be related to ROS production, mitochondrial injury and steatosis, 25 which are the common features of acute and chronic alcohol exposure (*Li et al. 2015. Int. J. Mol. Sci. 16: 26087–26124*).

Both **acute kidney injury (AKI)** and **chronic kidney disease (CKD)** that lead to diminished 30 kidney function are interdependent risk factors for increased mortality. If untreated over time, end stage renal disease (ESRD) is an inevitable outcome. Acute and chronic kidney diseases occur partly due to imbalance between the molecular mechanisms that govern oxidative stress, inflammation, autophagy and cell death. Numerous studies suggest oxidative stress and its systemic effects play a pivotal role in the development of AKI. A recent study

demonstrated an increased urinary thioredoxin 1 (TRX1) expression as an oxidative stress biomarker with respect to renal injury. Diabetic nephropathy (DN) is a devastating complication of diabetes and a major cause of CKD. In kidney, mitochondrial respiratory chain and NADPH oxidases (NOX) are the major common sources of ROS and NOX have 5 been demonstrated to produce oxidative stress by enhancing vascular dysfunction and fibrosis in CKD. For review see Sureshbabu et al. 2015. Redox Biology 4: 208–214.

Drug-induced kidney injury (nephrotoxicity) is a serious problem in clinical practice and accounts for 19%–26% of cases with acute kidney injury (AKI) among hospitalized patients. 10 Moreover, AKI causes a severe condition associated with high probabilities of developing progressive chronic kidney disease or end-stage renal disease, thus leading to high mortality rates. Most drugs found to cause nephrotoxicity exert toxic effects by one or more common pathogenic mechanisms. These include altered intraglomerular hemodynamics, tubular cell toxicity, inflammation, crystal nephropathy, rhabdomyolysis, and thrombotic 15 microangiopathy. AKI includes acute tubular necrosis (ATN) and acute interstitial nephritis (AIN). A mechanism underlying ATN is oxidative stress. Proximal tubular toxicity develops due to direct nephrotoxic effects such as mitochondrial dysfunction, lysosomal hydrolase inhibition, phospholipid damage, and increased intracellular calcium concentration, leading to formation of reactive oxygen species (ROS) with injurious oxidative stress (Hosohata 2016. 20 Int. J. Mol. Sci. 17: 1826).

Medications that are potentially harmful to the kidneys (nephrotoxic) are, e.g. antimicrobials like antibiotics (for example streptomycin, gentamicin) or antivirals (for example acyclovir, foscarnet) or antifungal (for example amphotericin B), analgesics, non-steroidal anti-inflammatory drugs (NSAID) (for example ibuprofen, naproxen), diuretics, 25 proton pump inhibitors, chemotherapeutics (for example cisplatin), contrast dyes, cardiovascular agents like ACE-inhibitors or statins, anti-depressants, immune suppressants (for example cyclosporine A) and antihistamines (for reference see Naughton 2008. Am Fam Physician. 2008;78(6):743-750, Table 1; Hosohata 2016. Int. J. Mol. Sci. 17: 1826).

30

In **carcinogenesis**, high reactive hydroxyl radicals cause oxidative DNA damage and peroxynitrite, which causes both oxidative damage and nitration of DNA bases. The majority of mutations induced by ROS appear to involve guanine modification, causing guanine (G) →

thymin (T) transversions. If it relates to critical genes such as oncogenes or tumor suppressor genes, initiation or progression of cancer can result. The high metabolism of cancer cells is generally associated with an increase in ROS; however, such levels are less deleterious in cancer cells than they would be in normal cells. For example, although the ROS level 5 increases by a modest degree, tumorigenic cells can induce a new redox balance, resulting in cellular adaptation and proliferation. The ROS generated by the respiratory chain in the mitochondria and by the Nox enzymes in the cytoplasm are particularly important. In fact, Nox proteins are now considered to be oncogenic proteins, and mitochondrial dysfunction is associated with tumorigenesis. Oxidative stress is involved in all stages of carcinogenesis and 10 there is a dose-dependent association between level of the persistent or chronic oxidative stress and the tumor stage. During the carcinogenesis process the normal cells are transformed into abnormal cells owing to a number of structural changes and mutations in genes expression. In the subject literature carcinogenesis is described by three main stages: *initiation, promotion and progression*. All these stages have been postulated to be linked with 15 contribution of ROS and RNS. ROS have an important role in the pathophysiological states involved in neovascularization. For example ROS-generating enzymes, such as NADPH oxidases (e.g., Nox: Nox1-5), activate redox signaling pathways that ultimately lead to angiogenesis. For review see Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Sosa et al. 2013. Ageing Research Reviews 12: 376–390.

20

Prostate cancer is the most frequently diagnosed non-cutaneous malignancy in males. This is a multi-focal, filed-type disease, which forms solid tumors of glandular origin. Prostate cancer is mainly a disease of aging, with most cases occurring in men over the age of 55. Over the last decade association between prostate cancer risk and oxidative stress has been recognized, 25 and epidemiological, experimental and clinical studies have unequivocally proven a role for oxidative stress in the development and progression of this disease, commonly associated with a shift in the antioxidant-prooxidant balance towards increased oxidative stress. Environmental factors like diet, inflammation, and changes in cellular functions pertaining to NAD(P)H Oxidase, androgen signalling, mitochondrial DNA mutations, aging, and redox 30 imbalance are possible mechanisms that contribute to increase ROS generation. This increased ROS may further stimulate cell proliferation, cause somatic DNA mutations and promote genetic instability, cell cycle arrest, senescence, and in cancer cells can cause increased angiogenesis, and motility. Especially increased Nox expression driven ROS

generation in prostate cancer could lead to the generation of a malignant phenotype by modulating various signalling cascades. For review see *Khandrika et al. 2009. Cancer Lett. 282(2): 125–136; Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Sosa et al. 2013. Ageing Research Reviews 12: 376– 390.*

5

The excessive production of ROS in **breast cancer** cells include: a strong expression of thymine phosphorylase leading to degradation of thymidine to thymine and 2-deoxy-D-ribose phosphate; oxidation of 17-estradiol panoxy radicals to lactoperoxidase participating in metabolism of estrogens and inflammation. In addition to the increase in free radicals, 10 antioxidant changes are related to breast cancer risk, for example the levels of SOD and GPX were found to be higher in the blood of breast cancer cases compared to that of healthy women as a reply on the increased production of superoxide and hydrogen peroxide. In breast cancer, the tumor suppressor gene breast cancer gene 1 (BRCA1) is mutated in 40–50% of hereditary breast cancers and absent or expressed at low levels in 30–40% of sporadic breast 15 cancers. BRCA1 is a caretaker gene that is responsible for repairing DNA, and it is able to upregulate several genes involved in the antioxidant response by controlling the activity of the transcription factors Nrf2 and NfkB. Apart from the inhibitory action of BRCA1 on ROS generation, BRCA1 also reduces the levels of protein nitration due to RNS accumulation in cells, and it enhances DNA repair processes that ultimately help to cope with oxidative stress.

20 For review see *Nourazarian et al. 2014 Asian Pac J Cancer Prev, 15 (12): 4745-4751; Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Sosa et al. 2013. Ageing Research Reviews 12: 376– 390.*

25 The human lungs are exposed continuously to air pollution oxidants in addition to endogenously generated ROS and RNS, which are involved in physiological biochemical mechanisms and normal cellular signalling pathways. It is a commonly considered hypothesis that tobacco smoking is a key risk factor in **lung cancer** development. Both, clinical and experimental research has consistently shown the important role of OS in lung cancer. Evidence is available that supports the importance of oxidative stress and its correlation with 30 increased incidence of malignant respiratory diseases due to inflammation, activation of transcriptional factors and DNA damage. During inflammation, enhanced ROS production induces DNA damage, inhibition of apoptosis, and activation of protooncogenes by initiating signal transduction pathways. Inflammatory cells are particularly effective in generating ROS

and other reactive species, thus increasing oxidative damage and promoting mechanisms of carcinogenesis. The ability of respirable particles or fibrous dusts to penetrate the respiratory system and reach the lung alveoli in order to generate ROS and other oxidants or free radicals is suggested to be the main factor involved in their pathogenic potential. Synergistic 5 mechanisms of inhalable particulate matter (penetrating deep into the lung's alveoli) and other components of air pollution (ozone, nitric oxide, soot, heavy metals, PAHs) and tobacco smoke have been studied. The porous surfaces of airborne particles provide a fertile ground for catalyzing the increased generation of ROS or other damaging oxidants, which are potential initiators of pulmonary carcinogenesis. For review see *Valavanidis et al. 2013. Int. 10 J. Environ. Res. Public Health 10: 3886-3907; Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Sosa et al. 2013. Ageing Research Reviews 12: 376-390.*

15 **Colorectal cancer (CRC)** is one of the most common cancers worldwide, with the highest incidence rates in western countries. Colon cancer originates from the epithelial cells that line the bowel. These cells divide rapidly and have a high metabolic rate, which has been found as a potential factor that may be responsible for increased oxidation of DNA. It was found that the human colorectal tumors (adenomas and carcinomas) have increased levels of different 20 markers of oxidative stress, such as increased levels nitric oxide (NO), 8-oxodG in DNA, lipid peroxides, glutathione peroxidase (GPx), catalase (CAT), and decreased methylation of cytosine in DNA. Besides lipid modifications also increased leukocyte activation in carcinogenic tissue was found, which indicates possible contribution of inflammatory cells to a further oxidative stress. Moreover, it was shown that levels of anti-oxidant vitamins A, C, E 25 in blood plasma of colorectal cancer patients were statistically lower compared to healthy individuals. For review see *Perse 2013. BioMed Research International 725710; Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Sosa et al. 2013. Ageing Research Reviews 12: 376-390.*

30 In the industrialized countries, **bladder cancer** is the fourth most frequently occurring malignant tumors. Recent studies indicate the involvement of oxidative and nitrosative stress in the formation and development of this disease. Red-ox disorders are characteristic for both, the initiation and progression of bladder cancer. There are observed changes in the activity of transcription factors, such as nuclear factor NF- κ B; transcription factors: AP-1, Nrf2 and

STAT3 and hypoxia-inducible factor HIF-1 α . In addition, studies indicate a role for oxidative stress in the regulation of MAPK cascade and its involvement in carcinogenesis consisting bladder. Nitric oxide also plays an important role in tumor biology. Numerous studies show that the bladder cancer is characterized by an intensified production of NO. In contrast to the 5 ROS, which overproduction result from exposure to carcinogenic xenobiotic, nitrogen oxide in high level is produced during inflammation. Sustained iNOS activity therefore plays an important role in carcinogenesis associated with the inflammatory response, characteristic also for bladder cancer. For review see Sawicka et al. 2015. Postepy Hig Med Dosw 69: 744-752.

10

Ovarian cancer is the fifth leading cause of cancer death; the leading cause of death from gynecologic malignancies, and the second most commonly diagnosed gynecologic malignancy. The overwhelming majority of ovarian cancers are derived from ovarian surface epithelium. Metastasis is achieved through detachment of single cells or clusters of cells from 15 the primary tumor followed by implantation on peritoneal mesothelial lining. Ovarian, endometrial, and cervical cancer consist a great problem in oncology due to their diagnosis in advanced stage. Research finding have shown that oxidative stress plays a causal role in the carcinogenesis of two subtypes of ovarian cancer: clear cell carcinoma and endometriosis carcinoma. Evidence suggests that ovarian cancer patients have decreased levels of circulating 20 antioxidants and higher levels of oxidative stress. It has been reported that epithelial ovarian cancer (EOC) tissues and cells manifest a pro-oxidant state characterized by an increased expression of key pro-oxidant enzymes and decreased expression of antioxidant enzymes. Specifically, EOC cells and tissues manifested an increased expression of iNOS, MPO, NAD(P)H oxidase, as well as an increase in NO levels. Moreover, EOC cells manifested 25 lower apoptosis.

Endometrial cancer has been reported to be associated with endometriosis disease, and the high levels of free iron hemosiderin or heme in endometrial cysts are considered as a main factor responsible for the oxidative stress development and chronic inflammation.

30

Cervical cancer is the second most common cancer in women worldwide being a subject of intensive research. Several experimental studies suggested the participation of oxidative stress in cervical, indicating that antioxidants can alter the redox balance in cervical cancer cells,

inhibit transcription factors AP-1 and NF-κB or induce cell apoptosis. For review see Saed et al. 2017. Gynecologic Oncology 145: 595–602; Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Sosa et al. 2013. Ageing Research Reviews 12: 376–390.

5

Oxidative damage induced by OS has been also implicated in **leukemia** and the decreased levels of antioxidants and oxidatively modified DNA and lipids caused by high ROS production were found in serum of chronic lymphocytic leukemia patients. Moreover, it was found that the chronic leukemia cells were able to adapt to intracellular OS through upregulation the stress-responsive hemeoxygenase-1 confirming involvement of ROS in the pathogenesis of leukemia cancer. Also, GSH depletion in lymphocytes of the chronic lymphocytic has been demonstrated in leukemia B patients. For review see Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919.

10 15 **Gastric cancer (GC)** is one of the most frequent diseases in human population. It is the fourth frequent cancer and the second most common cause of deaths from cancer in the world. The main risk factor for gastric cancer is chronic inflammation caused by bacterial growth. For example, infection by *Helicobacter pylori*, which increases the production of reactive oxygen and nitrogen species in human stomach, is thought to be important in the development 20 of gastric cancer. It has been shown that protein oxidation products were significantly higher in GC patients. Moreover, it was found that the antioxidant potentials of SOD and catalase were lower in gastric cancer tissues compared to the control healthy tissues. For review see Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Ma et al. 2013. Oxidative Medicine and Cellular Longevity 543760.

25

There are many factors involved in **liver carcinogenesis**, including hepatitis B virus (HBV) and hepatitis C virus (HCV) infection, alcohol abuse, and nonalcoholic fatty liver disease (NAFLD), aflatoxin B1, obesity, diabetes, dietary habits, and iron accumulation. In general, oxidative stress can be triggered by any dangerous or inflammatory signal and affects multiple 30 cells in the liver. Liver injury can be either an acute or a chronic inflammatory process. In the environment of local inflammation, many types of liver cells, such as liver sinusoidal endothelial cells (LSECs), hepatic stellate cells (HSCs), dendritic cells (DCs), and Kupffer cells (KCs), are activated. These cells produce many kinds of immune mediators, cytokines,

and chemokines that may also lead to the production of oxidative stress. In recent years, studies on the relationship between oxidative stress and hepatic stellate cells have been increasing. These cells have been proven to play a central part in the process of liver fibrosis and can induce collagen production after activation in the body by free radicals, which are produced by ROS and superoxide anions, and further induce damage to liver cells.

It is known that over 80% of cases of HCC are associated with chronic HBV or HCV infection. HBV- and HCV-related chronic inflammation and fibrosis of the liver are usually induced by oxidative stress, which contributes to the pathogenesis of hepatocarcinogenesis.

10 HBV infection results in activation of macrophages to produce a variety of proinflammatory cytokines, such as IL-1 β , IL-6, CXCL-8, and TNF- α . Such persistent abnormal production of cytokines and the resulting production of ROS have an influence on hepatocarcinogenesis. HCV-induced oxidative stress contributes to the development of hepatocellular carcinoma (HCC). Moreover, levels of oxidative stress markers in chronic hepatitis C patients correlate 15 positively with the probability of development of HCC and can serve as prognostic markers for HCC recurrence in chronic hepatitis C patients who underwent liver transplantation. Carcinogenesis is orchestrated by multiple ROS-mediated processes. For review see Wang et al. 2016. Oxidative Medicine and Cellular Longevity 7891574.

20 Skin is a major environmental interface for the body, which accidentally or occupationally gets exposed to a number of chemical mutagens and carcinogens. **Skin cancer** represents a major and growing public health problem. It accounts for more than 40 % of all new cancer diagnosed. 80 % of skin cancers result from basal cell carcinomas (BCC); another 16 % are squamous cell carcinomas (SCC), and 4 % are melanomas. A large number of evidence 25 indicates that UV can induce DNA damage and as a consequence DNA strand breaks and DNA cross links are detected. An important process in skin cancer is generation of hydrogen peroxide by melanocytes and decrease in catalase activity. Moreover, there are findings showing that mutations in several genes linked with melanoma result from oxidative stress. For review see Kruk and Aboul-Einein 2017. Mini-Reviews in Medicinal Chemistry 17: 904-919; Narendhirakannan. 2013. Ind J Clin Biochem 28(2):110-115.

Reactive species generated during **infection** may have serious consequences for the disease once they are released to any degree. The oxidative stress can initiate adverse effects in

different organs. Development of oxidative stress can be accelerated in the course of hypoxia. Hypoxia is a known complication of infectious diseases. Hypoxia is not peculiar to one disease. Influenza, viral hepatitis and tuberculosis are all examples of infectious diseases in which hypoxia takes place. Direct generation of reactive oxygen species can be initiated by metals. In an example, iron, cooper, and cadmium can catalyze the development of oxidative stress by Fenton reaction in which hydrogen peroxide is converted into hydroxyl radical and hydroxide anion. Heavy metals are involved in pathological processes linked to infections like other pathologies. As mentioned, livers damaged by viral hepatitis are vulnerable to heavy metals due to faulty elimination processes. Clinical studies on patients with **viral hepatitis A, B, C, D, and E** demonstrated that accumulation of copper and iron caused oxidative stress and oxidative damage to patients' liver tissue. Like hepatitis, AIDS is accompanied by imbalance in oxidative homeostasis. Elevated markers of oxidative damage of targets in the body and accumulation of reactive oxygen species are common in **HIV-infected patients**. Blood antioxidants are reduced over the long term in the infected individuals. For review see Pohanka 2013. Folia Microbiol 58:503–513.

Sepsis and septic shock remain as leading cause of death in adult intensive care units. It is widely accepted that sepsis and septic shock are caused predominantly by gram-negative bacteria and their endotoxins. Endotoxin or Lipopolysaccharide (LPS) have important roles as host responses and trigger the inflammatory processes, caused by gram-negative bacterial infection. Production of oxygen radicals by neutrophils and macrophages such as reactive oxygen species (ROS), NO (nitric oxide) and peroxynitrite promote gene expression of proinflammatory mediators. ROS and RNS are antimicrobial agents produced by these leukocytes that can directly destroy microbial pathogens. During sepsis, excess production of ROS and RNS threatens the integrity of various biomolecules including proteins, lipids as well as lipoproteins, protein oxidation and DNA resulting in tissue damage, by lipid peroxidation of cell membranes, protein oxidation and DNA strand breaks. These mechanisms contribute to multi organ failure during sepsis resulting in myocardial depression, hepatocellular dysfunction, endothelial dysfunction, and vascular catecholamine hyporesponsiveness. As a major source of ROS production, mitochondria are especially prone to ROS-mediated damage. Such damage can induce the mitochondrial permeability transition caused by opening of nonspecific high conductance permeability transition pores in the mitochondrial inner membrane. ROS themselves also provide a signal leading to the induction

of autophagy, apoptosis, and necrosis. Excessive ROS production and adenosine triphosphate depletion from uncoupling of oxidative phosphorylation promote necrotic cell death. Release of cytochrome-c after mitochondrial swelling activates caspases and initiates apoptotic cell death. For review see *Kaymak et al. 2011. FABAD J. Pharm. Sci. 36: 41-47.*

5

Thus, in another specific embodiment of the invention the herein disclosed DPP3 binder, specifically the herein provided anti-DDP3 antibody, and/or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold which are binding to an epitope according to SEQ ID NO.: 2, which is comprised in a DPP3 protein or a functional derivative thereof are provided for the

10 use in the prevention or treatment of a disease or acute condition of a patient, whereby said disease or acute condition is associated with oxidative stress, said disease is selected from the group comprising the above described neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic 15 shock and SIRS.

In another specific embodiment said disease is selected from the group comprising neurodegenerative diseases (e.g. Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)), 20 metabolic syndrome (including insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes), cardiovascular disorders (e.g. atherosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury/ stroke and myocardial infarction), autoimmune diseases (e.g. rheumatoid arthritis and systemic lupus erythematosus), inflammatory lung diseases (e.g. COPD, asthma), kidney diseases (including renal toxicity 25 (drug-induced kidney disease), acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD)), liver diseases (e.g. hepatotoxicity, viral hepatitis, cirrhosis), digestive diseases (including inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease; gastritis, pancreatitis and peptic ulcer), viral infectious 30 diseases (e.g. blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus)), cancer (e.g. prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer) and inflammation, sepsis, septic shock and SIRS.

In another specific embodiment of the invention the herein disclosed DPP3 binder, specifically the herein provided anti-DDP3 antibody, and/or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold which are binding to an epitope according to SEQ ID NO.: 2, which is comprised in a DPP3 protein or a functional derivative thereof are provided for the 5 use in the prevention or treatment of an acute condition, wherein said acute condition may be selected from a group comprising hepatotoxicity and kidney toxicity.

Toxicities resultant from alcohol consumption, chronic exposure to cigarette smoke and as a side-effect of different drug treatments

10 In the context of the present invention, oxidative stress and subsequent toxicities can also be induced by chronic alcohol consumption, chronic exposure to cigarette smoke and as a side-effect of different drug treatments (reviewed in Deavall et al. 2012, see table 2 below).

15 Acetaminophen – a widely used analgesic and antipyretic drug – is a prototypical hepatotoxicant for drug-induced liver injury that is connected to KEAP-Nrf2 signaling (Ma, 2013). Other therapeutics inducing oxidative stress include oltipraz and auranofin (Ma, 2013).

Table 2: Examples of toxicities associated with drug-induced oxidative stress (from Deavall et al. 2012)

Therapeutic class	Drug	Example toxicities	Evidence for oxidative stress
Antineoplastic (anthracycline)	Doxorubicin	Cardiac toxicity	Reduction of doxorubicin to free radical increases ROS in cardiomyocytes. Lipid peroxidation, mitochondrial dysfunction, apoptosis
Antiretroviral	AZT	Skeletal myopathy, cardiac toxicity	Increased ROS and NOS (peroxide and peroxynitrate). Overexpression of superoxidase dismutase/catalase protects against toxicity, apoptosis
Anti-inflammatory	Diclofenac	Nephrotoxicity, hepatotoxicity	Oxidative stress generated by a cation radical or redox cycling of intermediates derived from hydroxylation. Multifactorial perturbations in mitochondrial dysfunction
Analgesia	Paracetamol	Hepatotoxicity	Formation of reactive metabolite, depletion of glutathione, activation of proapoptotic proteins. Mitochondrial dysfunction, inflammation
Antineoplastic (platinum)	Cisplatin	Nephrotoxicity, ototoxicity	Increases in superoxide anion, hydrogen peroxide, and hydroxyl radical. Depletion of antioxidants GSH-peroxidase and GSH-reductase. Mitochondrial dysfunction, apoptosis
Antipsychotic	Chlorpromazine	Dermal toxicity (due to phototoxicity)	Generation of singlet oxygen and superoxide in response to UVA/B irradiation

5 In accordance with the present invention, the person skilled in the art is well aware that the presence and degree of oxidative stress may be determined and quantified by suitable

biomarker assays known in the art. Respective examples for these markers are given below, but these shall be not construed as limiting possibilities to measure oxidative stress in accordance with the invention:

5 **Markers of oxidative stress for assessment: Serum, Erythrocytes, CSF, Saliva, Urine**

Free radicals can damage biological molecules including nucleic acids, proteins, and lipids. The products of these reactions can become markers of oxidative stress. Serum is the most common material for the evaluation of the components of oxidative stress. It allows the estimation of most enzymes, substrates, and products of redox reactions. These enzymes

10 include xanthine oxidase, NOS, lipoxygenase, cyclooxygenase, myeloperoxidase, prolyl-oligopeptidase, nicotinamide adenine dinucleotide phosphate-oxidase 1 (NOX1), and NADPH-dependent oxidase. The following are markers of oxidative lipid damage: isoprostanes (IsoP-prostaglandin like substances), for example, 8-iso-prostaglandin (F_{2α}-8-iso-PGF_{2α}) which constitutes the product of lipid peroxidation of arachidonic acid, 15 malondialdehyde (MDA), the formation of fluorescent peroxidized lipid-protein covalent adducts, and the increase in conjugated diene. Oxidative stress involves the oxidation of proteins and glycoxidation. The following are the results of this reaction: the glycophore content, the total level of advanced protein oxidation (AOPP), protein carbonyls, dityrosine level, N'-formylkynurenine, and a decreased level of serum protein thiol groups. Other 20 specific markers of protein oxidation are tyrosine (a marker for hydroxyl radical) and 3-nitrotyrosine (a marker for RNS). Furthermore, 3-nitrotyrosine is a specific marker of peroxynitrite-induced cellular damage. Other indicators in the serum include kynurenine, N'-formylkynurenine, thioredoxin, and 8-hydroxy-2'-deoxyguanosine.

25 Respective measurements of biomarkers for oxidative stress in humans are summarized in Ilaria Marrocco, Fabio Altieri, and Ilaria Peluso; Review Article: Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans; *Oxidative Medicine and Cellular Longevity* Volume 2017 (2017), Article ID 6501046, 32 pages.

30 Moreover, in accordance with the present invention, the person skilled in the art is well aware that the bioactivity of DPP3, which is influenced by the herein disclosed DPP3 binder, can be measured for e.g. inhibition via suitable assays known in the art. Respective examples are

given below, but these shall be not construed as limiting possibilities to determine DPP3 bioactivity:

Method for detecting and measuring the inhibition of DPP3

5

Inhibition of DPP3 activity in a liquid phase assay by a binder may be determined as followed: Blood samples (e.g. serum, heparin-plasma, Li-plasma, citrate-plasma, whole blood) of patients before and after anti-DPP3 antibody treatment is incubated with specific DPP3 substrates in a liquid phase assay. The specific liquid phase DPP3 activity assay to

10 determine the inhibitory ability of inhibitory DPP3 antibodies in blood samples comprises the following steps:

- Addition of 20 µl blood sample in 200 µl 50 mM Tris-HCl, pH 7,5 in a black non-binding microtiter plate (96-well). Hereby, the person skilled in the art is aware that buffering conditions, concentrations and pH etc. can be varied.
- Addition of the fluorogenic substrate Arg-Arg-βNA (20 µl, 2 mM).
- Incubation at 37 °C and monitoring the generation of free βNA in a Twinkle LB 970 microplate fluorometer (Berthold Technologies GmbH) over 1 hour. Fluorescence of βNA is detected by exciting at 340 nm and measuring emission at 410 nm.
- Slopes (in RFU/ min) of increasing fluorescence of the different samples are calculated.
- Analysis of DPP3 activity values before and after anti-DPP3 antibody treatment.

In contrast thereto a solid phase assay is an assay where the respective binding events take place at the solid phase. Inhibition of DPP3 activity in a solid phase assay by a binder may be determined as followed according: Blood samples (e.g. serum, plasma, whole blood) of patients before and after anti-DPP3 antibody treatment are contacted with an immobilized capture-binder for enzyme capture activity assay (ECA) on a solid phase. Preferably, as capture-binder for the ECA is chosen the one with the least inhibitory ability. The capture-binder should inhibit DPP3 activity less than 50 %, preferably less than 40 %, preferably less than 30 %. The specific liquid phase DPP3 activity assay to determine the inhibitory ability of possible capture-binders is described in detail in Example 1 below.

The ECA to determine the inhibitory ability of inhibitory DPP3 antibodies in blood samples comprises the following steps:

- 5 • Contacting said sample with a capture-binder that binds to full-length DPP3 but preferably inhibits DPP3 activity in a liquid phase assay less than 50%, preferably less than 40%, more preferably 30%
- Separating DPP3 bound to said capture binder from bodily fluid sample,
- Adding substrate of DPP3 to said separated DPP3,
- Quantifying DPP3 activity by measuring the conversion of the substrate of DPP3,
- 10 • Evaluation of measured signals and analysis of DPP3 activity values before and after anti-DPP3 antibody treatment.

The method for determining active DPP3 may be conducted as liquid phase assay and as solid phase assay. Inhibition of DPP3 activity may be determined in a liquid assay nevertheless 15 according to the above-described procedure.

In yet another embodiment, a capture or binding assay may be performed to detect and/or quantitate the protease activity of DPP3. For example, an antibody reactive with DPP3 protein, but which does not interfere with peptidase activity, may be immobilized upon a solid 20 phase. The test sample is passed over the immobile antibody, and DPP3, if present, binds to the antibody and is itself immobilized for detection. A substrate may then be added, and the reaction product may be detected to indicate the presence or amount of DPP3 in the test sample. For the purposes of the present description, the term "solid phase" may be used to include any material or vessel in which or on which the assay may be performed and includes, 25 but is not limited to, porous materials, nonporous materials, test tubes, wells, slides, etc.

Moreover, in accordance with the present invention, the person skilled in the art is well aware that the binding affinity of the herein disclosed DPP3 binder to DPP3 may be measured by various suitable assays known in the art. Respective examples are given below, but these shall 30 be not construed as limiting possibilities to measure binding affinity of the herein disclosed DPP3 binder to DPP3:

Method for measuring the binding affinity of the DPP3 binder of the invention to the epitope according to sequence SEQ ID NO.: 2

5 The binding affinity of the DPP3 binder to the epitope according to SEQ ID NO.: 2 in accordance with the invention may be determined in accordance with Example 1 and as further set out below:

10 A binding assay may be performed to detect and/or quantitate antibody binding to the immunization peptide (i.e. SEQ ID NO.: 2). For example, this immunization peptide may be immobilized upon a solid phase. The test sample (e.g. antibody solution) is passed over the immobile immunization peptide, and bound antibody can be detected. For the purposes of the present description, the term "solid phase" may be used to include any material or vessel in which or on which the assay may be performed and includes, but is not limited to, porous materials, nonporous materials, test tubes, wells, slides, etc.

15

Exemplary detection methods:

20

- Label antibody before contacting with solid phase and detect respective label (fluorescence, chemiluminescence, enzymatic etc.)
- Use labeled secondary antibody against specific Fc part of sample-antibody. Incubate solid phase bound antibody with secondary antibody (e.g. anti human IgG, anti murine IgG) and detect respective label (fluorescence, chemiluminescence, enzymatic etc.)
- Use a labeled antibody as competitor for solid phase binding (e.g. labeled AK1967).
- Quantify binding affinity by decrease of signal.

25

FURTHER DESCRIPTION OF THE INVENTION**Binder directed against circulating, intracellular, membranous DPP3**

30 In another embodiment of the invention, the herein disclosed binder of the invention, and DPP3 binder, specifically the anti-DPP3 antibodies, anti-DPP3 antibody fragments, or anti-DPP3 non-Ig scaffolds are capable to bind circulating DPP3, and thus are directed against circulating DPP3.

In yet another embodiment of the invention, the herein disclosed binder of the invention, and DPP3 binder, specifically the anti-DPP3 antibodies, anti-DPP3 antibody fragments, or anti-DPP3 non-Ig scaffolds are capable to bind intracellular DPP3, and thus are directed against intracellular DPP3.

5

In yet another embodiment of the invention, the herein disclosed binder of the invention, DPP3 binder, specifically the anti-DPP3 antibodies, anti-DPP3 antibody fragments, or anti-DPP3 non-Ig scaffolds are capable to bind membranous DPP3, and thus are directed against membranous DPP3.

10

Also subject matter of the present invention, are the herein disclosed binder of the invention, DPP3 binder, specifically is an anti-DPP3 antibody or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said diseases or acute conditions are associated with oxidative stress, and whereby said binder, DPP3 binder, specifically is an anti-DPP3 antibody or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold are directed to and binding to an epitope of SEQ ID NO.: 2, wherein said epitope is comprised in a circulating DPP3 protein or functional derivative thereof.

20 Also subject matter of the present invention, are the herein disclosed binder of the invention , DPP3 binder, specifically an anti-DPP3 antibody or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said diseases or acute conditions are associated with oxidative stress, and whereby said binder, DPP3 binder, specifically an anti-DPP3 antibody or an anti-25 DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold are directed to and binding to an epitope of SEQ ID NO.: 2, wherein said epitope is comprised in an intracellular DPP3 protein or functional derivative thereof.

Also subject matter of the present invention, are the herein disclosed binder of the invention, 30 DPP3 binder, specifically an anti-DPP3 antibody or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said diseases or acute conditions are associated with oxidative stress, and whereby said DPP3 binder, specifically an anti-DPP3 antibody or an anti-DPP3

antibody fragment or an anti-DPP3 non-Ig scaffold are directed to and binding to an epitope of SEQ ID NO.: 2, wherein said epitope is comprised in a membranous DPP3 protein or functional derivative thereof.

5 Subject matter of the present invention is further a method for regulating and/or preventing or treatment of oxidative stress in a patient having a chronic or acute disease or acute condition, characterized in that to said patient a binder of the invention, or a DPP3 binder of the invention, specifically an anti-DPP3 antibody or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold is administered in pharmaceutically effective amounts. According to

10 10 the invention said patient is a patient in need of regulating and/or preventing or in need of treatment of oxidative stress.

Pharmaceutical composition

Another subject of the present invention is a pharmaceutical composition comprising the
15 herein disclosed binder of the invention, or DPP3 binder, specifically comprising an anti-DPP3 antibody or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold for use in the prevention or treatment of diseases or acute conditions of a patient, wherein said disease or acute condition is associated with oxidative stress.

20 In another embodiment of the present invention said pharmaceutical composition is a solution, preferably a ready-to-use solution.

In another embodiment of the present invention said pharmaceutical composition is a solution, preferably a ready-to-use solution comprising PBS at a pH of 7.4.

25 In another embodiment of the present invention said pharmaceutical composition is in a dried state that is to be reconstituted before use.

30 In another embodiment of the present invention said pharmaceutical composition is in a freeze-dried state that is to be reconstituted before use.

Administration routes

In another embodiment of the present invention said pharmaceutical composition that is to be used in the prevention and/or treatment of a disease or an acute condition of a patient, wherein said disease or acute condition is associated with oxidative stress is administered orally, epicutaneously, subcutaneously, intradermally, sublingually, intramuscularly, intraarterially, 5 intracerebrally, intracerebroventricularly, intravenously, or via the central nervous system (CNS) or via intraperitoneal administration.

Kit

Another embodiment of the present invention is a kit or an assay comprising the herein 10 disclosed binder of the invention, or DPP3 binder, specifically comprising an anti-DPP3 antibody or an anti-DPP3 antibody fragment or an anti-DPP3 non-Ig scaffold for use in the prevention or treatment of a disease or acute condition of a patient, whereby said disease or acute condition is associated with oxidative stress.

15 **Specifically binding antibodies**

In accordance with the invention the “anti-DPP3 antibody” is an antibody that binds specifically to DPP3, an “anti-DPP3 antibody fragment” is a fragment of said anti-DPP3 antibody, wherein said fragment binds specifically to DPP3. An “anti-DPP3 non-Ig scaffold” is a non-Ig scaffold that binds specifically to DPP3.

20

With the context of the invention, “specifically binding to DPP3” may also allow binding to other antigens as well. This means, this specificity would not exclude that the binder may cross-react with other proteins or polypeptides or peptides that contain the epitope according to SEQ ID NO.: 2 against which the binder has been raised. This specifically includes 25 functional variants of DPP3, which also comprise an epitope according to SEQ ID NO.: 2. This also pertains to the specificity of the anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold in accordance with the invention.

Antibody

30 An “antibody” according to the present invention is a protein including one or more polypeptides substantially encoded by immunoglobulin genes that specifically binds an antigen. The recognized immunoglobulin genes include the kappa, lambda, alpha (IgA), gamma (IgG₁, IgG₂, IgG₃, IgG₄), delta (IgD), epsilon (IgE) and mu (IgM) constant region

genes, as well as the myriad immunoglobulin variable region genes. Full-length immunoglobulin light chains are generally about 25 kDa or 214 amino acids in length.

Full-length immunoglobulin heavy chains are generally about 50 kDa or 446 amino acids in length. Light chains are encoded by a variable region gene at the NH₂-terminus (about 110 amino acids in length) and a kappa or lambda constant region gene at the COOH-terminus. Heavy chains are similarly encoded by a variable region gene (about 116 amino acids in length) and one of the other constant region genes.

10 The basic structural unit of an antibody is generally a tetramer that consists of two identical pairs of immunoglobulin chains, each pair having one light and one heavy chain. In each pair, the light and heavy chain variable regions bind to an antigen, and the constant regions mediate effector functions. Immunoglobulins also exist in a variety of other forms including, for example, Fv, Fab, and F(ab')₂, as well as bifunctional hybrid antibodies and single chains

15 (e.g., Lanzavecchia et al., *Eur. J. Immunol.* 17:105,1987; Huston et al., *Proc. Natl. Acad. Sci. U.S.A.*, 85:5879-5883, 1988; Bird et al., *Science* 242:423-426, 1988; Hood et al., *Immunology*, Benjamin, N.Y., 2nd ed., 1984; Hunkapiller and Hood, *Nature* 323:15-16,1986).

20 An immunoglobulin light or heavy chain variable region includes a framework region interrupted by three hypervariable regions, also called complementarity determining regions (CDR's) (see, *Sequences of Proteins of Immunological Interest*, E. Kabat et al., U.S. Department of Health and Human Services, 1983). As noted above, the CDRs are primarily responsible for binding to an epitope of an antigen. An immune complex is an antibody, such as a monoclonal antibody, chimeric antibody, humanized antibody or human antibody, or

25 functional antibody fragment, specifically bound to the antigen.

30 “Chimeric antibodies” are antibodies whose light and heavy chain genes have been constructed, typically by genetic engineering, from immunoglobulin variable and constant region genes belonging to different species. For example, the variable segments of the genes from a mouse monoclonal antibody can be joined to human constant segments, such as kappa and gamma 1 or gamma 3. In one example, a therapeutic chimeric antibody is thus a hybrid protein composed of the variable or antigen-binding domain from a mouse antibody and the constant or effector domain from a human antibody, although other mammalian species can

be used, or the variable region can be produced by molecular techniques. Methods of making chimeric antibodies are well known in the art, *e.g.*, see U.S. Patent No. 5,807,715. A "humanized" immunoglobulin is an immunoglobulin including a human framework region and one or more CDRs from a non-human (such as a mouse, rat, or synthetic) immunoglobulin. The non-human immunoglobulin providing the CDRs is termed a "donor" and the human immunoglobulin providing the framework is termed an "acceptor."

In one embodiment of the invention, all the CDRs are from the donor immunoglobulin in a humanized immunoglobulin. Constant regions need not be present, but if they are, they must be substantially identical to human immunoglobulin constant regions, *i.e.*, at least about 85-90%, such as about 95% or more identical. Hence, all parts of a humanized immunoglobulin, except possibly the CDRs, are substantially identical to corresponding parts of natural human immunoglobulin sequences.

A "humanized antibody" in accordance with the invention is an antibody comprising a humanized light chain and a humanized heavy chain immunoglobulin. A humanized antibody binds to the same antigen as the donor antibody that provides the CDRs. The acceptor framework of a humanized immunoglobulin or antibody may have a limited number of substitutions by amino acids taken from the donor framework. Humanized or other monoclonal antibodies can have additional conservative amino acid substitutions which have substantially no effect on antigen binding or other immunoglobulin functions. Exemplary conservative substitutions are those such as gly, ala; val, ile, leu; asp, glu; asn, gln; ser, thr; lys, arg; and phe, tyr. Humanized immunoglobulins can be constructed by means of genetic engineering (*e.g.*, see U.S. Patent No. 5,585,089). A human antibody is an antibody wherein the light and heavy chain genes are of human origin. Human antibodies can be generated using methods known in the art. Human antibodies can be produced by immortalizing a human B cell secreting the antibody of interest. Immortalization can be accomplished, for example, by EBV infection or by fusing a human B cell with a myeloma or hybridoma cell to produce a trioma cell. Human antibodies can also be produced by phage display methods (see, *e.g.*, Dower *et al.*, PCT Publication No. WO 91/17271; McCafferty *et al.*, PCT Publication No. WO 92/001047; and Winter, PCT Publication No. WO 92/20791), or selected from a human combinatorial monoclonal antibody library (see the Morphosys website). Human antibodies can also be prepared by using transgenic animals carrying a human

immunoglobulin gene (for example, see Lonberg *et al.*, PCT Publication No. WO 93/12227; and Kucherlapati, PCT Publication No. WO 91/10741).

Thus, the anti-DPP3 antibody or anti-DPP3 antibody fragment in accordance with the 5 invention may have the formats known in the art. Examples are human antibodies, monoclonal antibodies, humanized antibodies, chimeric antibodies, CDR-grafted antibodies or antibody fragments thereof, but not limited to.

Monoclonal antibody

10 In a specific embodiment of the invention the anti-DPP3 antibody is a monoclonal antibody or a fragment thereof. In one embodiment of the invention the anti-DPP3 antibody or the anti-DPP3 antibody fragment is a human or humanized antibody or derived therefrom. In one specific embodiment one or more (murine) CDR's are grafted into a human antibody or antibody fragment.

15

In a preferred embodiment antibodies according to the present invention are recombinantly produced antibodies as *e.g.* IgG, a typical full-length immunoglobulin, or antibody fragments containing at least the F-variable domain of heavy and/or light chain as *e.g.* chemically coupled antibodies (fragment antigen binding) including but not limited to Fab-fragments 20 including Fab minibodies, single chain Fab antibody, monovalent Fab antibody with epitope tags, *e.g.* Fab-V5Sx2; bivalent Fab (mini-antibody) dimerized with the CH3 domain; bivalent Fab or multivalent Fab, *e.g.* formed via multimerization with the aid of a heterologous domain, *e.g.* via dimerization of dHLX domains, *e.g.* Fab-dHLX-FSx2; F(ab')2-fragments, scFv-fragments, multimerized multivalent and/or multispecific scFv-fragments, bivalent 25 and/or bispecific diabodies, BITE® (bispecific T-cell engager), trifunctional antibodies, polyvalent antibodies, *e.g.* from a different class than G; single-domain antibodies, *e.g.* nanobodies derived from camelid or fish immunoglobulines and numerous others.

Non-Ig scaffolds

30 In addition to anti-DPP3 antibodies or anti-DPP3 antibody fragments, other biopolymer scaffolds, so called non-Ig scaffolds, are well known in the art to complex a target molecule and have been used for the generation of highly target specific biopolymers. Examples are aptamers, spiegelmers, anticalins and conotoxins.

Non-Ig scaffolds with the context of the invention may be protein scaffolds and may be used as antibody mimics as they are capable to bind to ligands or antigens. Non-Ig scaffolds may be selected from the group comprising tetranectin-based non-Ig scaffolds (e.g. described in 5 US 2010/0028995), fibronectin scaffolds (e.g. described in EP 1266 025; lipocalin-based scaffolds (e.g. described in WO 2011/154420); ubiquitin scaffolds (e.g. described in WO 2011/073214), transferring scaffolds (e.g. described in US 2004/0023334), protein A scaffolds (e.g. described in EP 2231860), ankyrin repeat based scaffolds (e.g. described in WO 2010/060748), microprotein (preferably microproteins forming a cystine knot) scaffolds 10 (e.g. described in EP 2314308), Fyn SH3 domain based scaffolds (e.g. described in WO 2011/023685), EGFR-A-domain based scaffolds (e.g. described in WO 2005/040229) and Kunitz domain based scaffolds (e.g. described in EP 1941867). Non-Ig scaffolds may be peptide or oligonucleotide aptamers. Aptamers are usually created by selecting them from a large random sequence pool and are either short strands of oligonucleotides (DNA, RNA or 15 XNA; Xu et al. 2010, Deng et al. 2014) or short variable peptide domains attached to a protein scaffold (Li et al. 2011).

Fragments and fusion proteins

In an alternative embodiment the anti-DPP3 antibody format is selected from the group 20 comprising Fv fragment, scFv fragment, Fab fragment, scFab fragment, F(ab)₂ fragment and scFv-Fc Fusion protein. In another preferred embodiment the antibody format is selected from the group comprising scFab fragment, Fab fragment, scFv fragment and bioavailability optimized conjugates thereof, such as PEGylated fragments.

25 Monoclonal / polyclonal antibodies

With the context of the invention, the term “antibody” generally comprises monoclonal and 30 polyclonal antibodies and binding fragments thereof, in particular Fc-fragments as well as so called “single-chain-antibodies” (Bird et al. 1988), chimeric, humanized, in particular CDR-grafted antibodies, and di- or tetrabodies (Holliger et al. 1993). Also comprised are immunoglobulin-like proteins that are selected through techniques including, for example, phage display to specifically bind to the molecule of interest contained in a sample. In this context the term “specific binding” refers to antibodies raised against the molecule of interest or a fragment thereof. An antibody is considered to be specific, if its affinity towards the

molecule of interest or the aforementioned fragment thereof is at least preferably 50-fold higher, more preferably 100-fold higher, most preferably at least 1000-fold higher than towards other molecules comprised in a sample containing the molecule of interest. It is well known in the art how to make antibodies and to select antibodies with a given specificity.

5

In a specific embodiment of the invention said anti-DPP3 antibody or anti-DPP3 antibody fragment binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or functional derivative thereof is a monoclonal antibody or a monoclonal antibody fragment thereof. In one embodiment of the invention the anti-DPP3

10 antibody or the anti-DPP3 antibody fragment binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or functional derivative thereof is a human or humanized antibody or derived therefrom or humanized antibody fragment or derived therefrom.

15 In one specific embodiment one or more (murine) CDR's are grafted into a human antibody or antibody fragment.

A modulating anti-DPP3 antibody

In a specific embodiment said DPP3 binder of the invention, specifically said anti-DPP3 20 antibody, anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold is a modulating DPP3 binder, anti-DPP3 antibody, anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold.

A modulating DPP3 binder, anti-DPP3 antibody, anti-DPP3 antibody fragment or anti-DPP3 25 non-Ig scaffold of the invention may act inhibitory and may block the bioactivity of DPP3 to nearly 100%, preferably to at least more than 90%, more preferably to at least 80, or 70, or 60, or 50, or 40, or 30, or 20, or 10 % when determined by means of the above described method for detecting and measuring the inhibition of DPP3; i.e. measuring the DPP3 binder influence on DPP-3 bioactivity.

30 In another specific embodiment, a modulating DPP3 binder, anti-DPP3 antibody, anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold of the invention may act upregulating and thus may enhance the bioactivity of DPP3 to at least 50 %, preferably to at least more than 60 %, more preferably to at least more than 70 %, more preferably to at least more than 80 %,

even more preferably to at least more than 90 %, even more so preferably to at least 95 % when determined by means of the above described method for detecting and measuring the inhibition of DPP3; i.e. measuring the DPP3 binder influence on DPP-3 bioactivity.

5 **Synthesis of anti-DPP3 antibodies**

Anti-DPP3 antibodies according to the present invention may be synthesised as follows:

DPP3 peptides for immunization were synthesized, see table 3 below, (JPT Technologies, Berlin, Germany) with an additional N-terminal cysteine (if no cystein is present within the

10 selected DPP3-sequence) residue for conjugation of the peptides to Bovine Serum Albumin (BSA). The peptides were covalently linked to BSA by using Sulfolink-coupling gel (Perbio-science, Bonn, Germany). The coupling procedure was performed according to the manual of Perbio. Recombinant GST-hDPP3 was produced by USBio.

15 Balb/c mice were intraperitoneally (i.p.) injected with 84 µg GST-hDPP3 or 100 µg DPP3-peptide-BSA-conjugates at day 0 (emulsified in TiterMax Gold Adjuvant), 84 µg or 100 µg at day 14 (emulsified in complete Freund's adjuvant) and 42 µg or 50 µg at day 21 and 28 (in incomplete Freund's adjuvant). At day 49 the animal received an intravenous (i.v.) injection of 42 µg GST-hDPP3 or 50 µg DPP3-peptide-BSA-conjugates dissolved in 20 saline. Three days later the mice were sacrificed and the immune cell fusion was performed.

Splenocytes from the immunized mice and cells of the myeloma cell line SP2/0 were fused with 1 ml 50% polyethylene glycol for 30 s at 37°C. After washing, the cells were seeded in 96-well cell culture plates. Hybrid clones were selected by growing in HAT medium [RPMI

25 1640 culture medium supplemented with 20% fetal calf serum and HAT-Supplement]. After one week, the HAT medium was replaced with HT Medium for three passages followed by returning to the normal cell culture medium.

The cell culture supernatants were primarily screened for recombinant DPP3 binding IgG 30 antibodies two weeks after fusion. Therefore, recombinant GST-tagged DPP3 (USBiologics, Salem, USA) was immobilized in 96-well plates (100 ng/ well) and incubated with 50 µl cell culture supernatant per well for 2 hours at room temperature. After washing of the plate, 50 µl / well POD-rabbit anti mouse IgG was added and incubated for 1 h at RT.

After a next washing step, 50 µl of a chromogen solution (3,7 mM o-phenylenediamin in citrate/hydrogen phosphate buffer, 0.012 % H₂O₂) were added to each well, incubated for 15 minutes at RT and the chromogenic reaction stopped by the addition of 50 µl 4N sulfuric acid.

5 Absorption was detected at 490 nm.

The positive tested microcultures were transferred into 24-well plates for propagation. After retesting the selected cultures were cloned and recloned using the limiting-dilution technique and the isotypes were determined.

10

Antibodies raised against GST-tagged human DPP3 or DPP3-peptides were produced via standard antibody production methods (Marx et al. 1997) and purified via Protein A. The antibody purities were ≥ 90 % based on SDS gel electrophoresis analysis.

15 **Humanization of murine antibodies**

Humanization of murine antibodies may be conducted according to the following procedure:

For humanization of an antibody of murine origin the antibody sequence is analyzed for the structural interaction of framework regions (FR) with the complementary determining regions 20 (CDR) and the antigen. Based on structural modelling an appropriate FR of human origin is selected and the murine CDR sequences are transplanted into the human FR. Variations in the amino acid sequence of the CDRs or FRs may be introduced to regain structural interactions, which were abolished by the species switch for the FR sequences. This recovery of structural interactions may be achieved by random approach using phage display libraries or via 25 directed approach guided by molecular modeling (Almagro JC, Fransson J., 2008. Humanization of antibodies. *Front Biosci.* 2008 Jan 1;13:1619-33).

CDR-grafted antibodies

In another aspect of the invention, the provided subject matter is a human CDR-grafted anti-30 DPP3 antibody or anti-DPP3 antibody fragment thereof that is directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said human CDR-grafted anti-DPP3 antibody or

anti-DPP3 antibody fragment thereof comprises an antibody heavy chain variable region (H chain) comprising

SEQ ID NO.: 5

5

and/or further comprises an antibody light chain variable region (L chain) comprising:

SEQ ID NO.: 6.

10 Further subject matter of the present invention in another aspect is a human CDR-grafted anti-DPP3 antibody or anti-DPP3 antibody fragment thereof that is directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein the said human CDR-grafted anti-DPP3 antibody or anti-DPP3 antibody fragment thereof comprises an antibody heavy chain variable region
15 (H chain) comprising:

SEQ ID NO.: 12

and/or further comprises an antibody light chain variable region (L chain) comprising:

20

SEQ ID NO.: 13.

In one specific embodiment of the invention subject matter of the present invention is a
25 human monoclonal anti-DPP3 antibody or monoclonal anti-DPP3 antibody fragment thereof that is directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein the heavy chain comprises at least one CDR of:

SEQ ID NO.: 7, SEQ ID NO.: 8 or SEQ ID NO.: 9

30

and wherein the light chain comprises at least one CDR of:

SEQ ID NO.: 8, KVS or SEQ ID NO.: 11.

With the above context, the variable region can be connected to any subclass of constant regions (IgG, IgM, IgE, IgA), or only scaffolds, Fab fragments, Fv, Fab and F(ab)2. In example 3 below, the murine antibody variant with an IgG2a backbone was used. For 5 chimerization and humanization a human IgG1κ backbone was used.

Epitope binding

For epitope binding only the Complementarity Determining Regions (CDRs) are of importance. The CDRs for the heavy chain and the light chain of the murine anti-DPP3 10 antibody of the present invention (AK1967) are shown in SEQ ID NO. 7, SEQ ID NO. 8 and SEQ ID NO. 9 for the heavy chain and SEQ ID NO. 10, sequence KVS and SEQ ID NO. 11 for the light chain, respectively.

Epitope binding sites

15 In accordance with the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibodies, anti-DPP3 antibody fragments and anti-DPP3 non Ig-scaffolds are directed to and binding to SEQ ID NO.: 1, and wherein said DPP3 binder, anti-DPP3 antibody, anti-DPP3 antibody fragment and anti-DPP3 non Ig-scaffold recognizes and binds to at least three aa, preferably at least 4 aa, more preferably at least 5 aa, even more 20 preferably at least 6 aa of said SEQ ID NO.:1.

In accordance with the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibodies, anti-DPP3 antibody fragments and anti-DPP3 non Ig-scaffolds are directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said 25 epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder, anti-DPP3 antibody, anti-DPP3 antibody fragment and anti-DPP3 non Ig-scaffold recognizes and binds to at least three aa, preferably at least 4 aa, more preferably at least 5 aa, even more preferably at least 6 aa of SEQ ID NO.: 2.

30 In another aspect of the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibodies, anti-DPP3 antibody fragments and anti-DPP3 non Ig-scaffolds are directed to and binding to an epitope according to SEQ ID NO.: 3, and wherein said epitope according to SEQ ID NO.: 3 is comprised in a DPP3 protein or a functional

derivative thereof, and wherein said DPP3 binder, anti-DPP3 antibody, anti-DPP3 antibody fragment and anti-DPP3 non Ig-scaffold recognizes and binds to at least three aa, preferably at least 4 aa, more preferably at least 5 aa, even more preferably to 6 aa of SEQ ID NO.: 3.

5 In another aspect of the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibodies, anti-DPP3 antibody fragments and anti-DPP3 non Ig-scaffolds are directed to and binding to an epitope according to SEQ ID NO.: 4, and wherein said epitope according to SEQ ID NO.: 4 is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder, anti-DPP3 antibody, anti-DPP3 antibody fragment and anti-DPP3 non Ig-scaffold recognizes and binds to at least three aa, preferably to four aa of SEQ ID NO.: 4.

10

Inhibitor or effector of the bioactivity of DPP3

In a specific embodiment of the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibodies, anti-DPP3 antibody fragments and anti-DPP3 non Ig-scaffolds which are directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, may act as inhibitor or effector of the bioactivity of DPP3.

20 Thus, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibodies, anti-DPP3 antibody fragments and anti-DPP3 non Ig-scaffolds which are directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof are useful in the prevention or treatment of a disease or acute condition in a patient, wherein said disease or acute condition is associated with oxidative stress in accordance with the invention.

25

Affinity

In a specific embodiment of the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibodies, anti-DPP3 antibody fragments and anti-DPP3 non Ig-scaffolds which are directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, exhibit an affinity towards DPP3 in such that the affinity constant is at least 10^{-7} M^{-1} , preferably at least 10^{-8} M^{-1} , more preferably the affinity constant is at least 10^{-9} M^{-1} , most preferred the

affinity constant is at least 10^{-10} M⁻¹ when determined by means of the methods for measuring the binding affinity of the DPP3 binder of the invention to the epitope according to sequence SEQ ID NO.: 2 as described above.

5 Thereby, a person skilled in the art knows that it may be considered to compensate lower affinity by applying a higher dose of binder; e.g. an anti-DPP3 antibody or anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold, and this measure would not lead out-of-the-scope of the invention.

10 **Drug combinations**

In another embodiment of the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibody or anti-DPP3 antibody fragment thereof or anti-DPP3 non-Ig scaffold may be used in combination with at least one additional drug that induces oxidative stress as side effect.

15 Such drugs are administered as primary medicament for use in the prevention or treatment of a primary disease and may be selected from a group comprising antimicrobials like antibiotics (for example streptomycin, gentamicin) or antivirals (for example acyclovir, foscarnet) or antifungal (for example amphotericin B), analgesics, non-steroidal anti-inflammatory drugs
20 (NSAID) (for example ibuprofen, naproxen), diuretics, proton pump inhibitors, chemotherapeutics (for example cisplatin), contrast dyes, cardiovascular agents like ACE-inhibitors or statins, anti-depressants, immune suppressants (for example cyclosporine A) and antihistamines. Thereby, and in accordance with the invention, the herein provided DPP3 binder, specifically the herein provided anti-DPP3 antibody or anti-DPP3 antibody fragment
25 thereof or a DPP3 non-Ig scaffold binding to DPP3 may be used as secondary medicament either in combination or as stand-alone drug in the prevention or treatment of the induced oxidative stress and resultant toxicities as secondary diseases.

Selective/specific binder

30 In a preferred embodiment of the invention the herein provided DPP3 binder are pharmaceutically acceptable, selective and/or specific for an epitope according to SEQ ID NO.: 2, which is comprised in a DPP3 protein or a functional derivative thereof.

In a more preferred embodiment of the invention the herein provided DPP3 binder is an inhibitory binder that is pharmaceutically acceptable, selective and/or specific for an epitope according to SEQ ID NO.: 2, which is comprised in a DPP3 protein or a functional derivative thereof.

5

In one aspect of the invention, selective and specific inhibitors of DPP3 do not bind to other proteins/peptides/enzymes or are bound by other proteins/peptides/enzymes, and do not inhibit any other enzyme/protease/peptidase other than DPP3. Therefore, the preferred inhibitors of DPP3 bioactivity with the context of the invention are specific anti-DPP3 antibodies, antibody fragments or non-Ig scaffolds binding to DPP3.

Monospecific antibody

Monospecific anti-DPP3 antibody or monospecific anti-DPP3 antibody fragment or monospecific anti-DPP3 non-Ig scaffold with the context of the invention means that said antibody or antibody fragment or non-Ig scaffold binds specifically to one specific region encompassing at least 3 amino acids, preferably at least 4 aa within the target DPP3.

With the context of the invention, monospecific anti-DPP3 antibody or monospecific anti-DPP3 antibody fragment or monospecific anti-DPP3 non-Ig scaffold are anti-DPP3 antibodies or anti-DPP3 antibody fragments or anti-DPP3 non-Ig scaffolds all have affinity for the same antigen as a target which is in accordance with the invention an epitope according to SEQ ID NO.: 2, which is comprised in a DPP3 protein or a functional derivative thereof.

In another specific embodiment, monospecific anti-DPP3 antibody or monospecific anti-DPP3 antibody fragment or monospecific anti-DPP3 non-Ig scaffold are anti-DPP3 antibodies or anti-DPP3 antibody fragments or anti-DPP3 non-Ig scaffolds all have affinity for the same antigen as a target which is in accordance with the invention an epitope according to SEQ ID NO.: 3, which is comprised in a DPP3 protein or a functional derivative thereof.

30 In another embodiment, monospecific anti-DPP3 antibody or monospecific anti-DPP3 antibody fragment or monospecific anti-DPP3 non-Ig scaffold are anti-DPP3 antibodies or anti-DPP3 antibody fragments or anti-DPP3 non-Ig scaffolds all have affinity for the same antigen as a target which is in accordance with the invention an epitope according to SEQ ID NO.: 4, which is comprised in a DPP3 protein or a functional derivative thereof.

Monospecific antibodies may also be produced by other means than producing them from a common germ cell.

5 With the above context, further preferred embodiments within the scope of the present invention are consecutively numbered below:

1. A binder directed to and binding to an epitope according to SEQ ID NO.: 2, and wherein said binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2, and wherein said epitope is comprised in SEQ ID NO.: 1, which corresponds to the amino acid sequence of DPP3.
- 10 2. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 of embodiment 1, wherein said binder is directed to and binding to an epitope according to SEQ ID NO.: 3, and wherein said binder recognizes and binds to at least three amino acids of SEQ ID NO.: 3, and wherein said epitope is comprised in SEQ ID NO.: 1, which corresponds to the amino acid sequence of DPP3.
- 15 3. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 of embodiment 1 or embodiment 2, wherein said binder is directed to and binding to an epitope according to SEQ ID NO.: 4, and wherein said binder recognizes and binds to at least three amino acids of SEQ ID NO.: 4, and wherein said epitope is comprised in SEQ ID NO.: 1, which corresponds to the amino acid sequence of DPP3.
- 20 4. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the embodiments 1 to 3, wherein said binder is selected from a group comprising an antibody or antibody fragment or non-Ig scaffold, and wherein said epitope is comprised in SEQ ID NO.: 1, which corresponds to the amino acid sequence of DPP3.
- 25 5. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding embodiments, wherein said binder is a dipeptidyl peptidase 3 (DPP3) binder directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

6. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding embodiments, wherein said binder is a monoclonal antibody or monoclonal antibody fragment, and wherein the complementarity determining regions (CDR's) in the heavy chain comprises the sequences:

5 SEQ ID NO.: 7, SEQ ID NO.: 8 and/ or SEQ ID NO.: 9

10 and the complementarity determining regions in the light chain comprises the sequences:

SEQ ID NO.: 10, KVS and/ or SEQ ID NO.: 11.

15 7. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding embodiments, wherein said binder is a human monoclonal antibody or human monoclonal antibody fragment, wherein the heavy chain comprises the sequence:

20 SEQ ID NO.: 12

25 and wherein the light chain comprises the sequence:

SEQ ID NO.: 13.

30 8. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding embodiments for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress.

9. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to embodiment 8, wherein said diseases are selected from a group comprising neurodegenerative

diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic shock and SIRS.

5 10. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to embodiment 8 or 9, and wherein said:

10 ○ neurodegenerative disease may be selected from a group comprising Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)),

15 ○ metabolic syndrome may be selected from a group comprising insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes,

20 ○ cardiovascular disorder may be selected from a group comprising atherosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction,

25 ○ autoimmune disease may be selected from a group comprising rheumatoid arthritis, systemic lupus erythematosus,

30 ○ inflammatory lung disease may be selected from a group comprising COPD, asthma,

 ○ kidney disease may be selected from a group comprising acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD),

 ○ liver disease may be selected from a group comprising viral hepatitis, and cirrhosis,

 ○ digestive disease may be selected from a group comprising inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease, gastritis, pancreatitis and peptic ulcer,

 ○ viral infectious disease may be selected from a group comprising blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus,

- cancer may be selected from a group comprising prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer,
- inflammation,
- sepsis, septic shock, SIRS.

5

11. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the 10 embodiments 8 to 10, wherein said disease is selected from a group comprising sepsis, septic shock, and SIRS.

10

12. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said 15 disease or acute condition is associated with oxidative stress according to embodiment 8, wherein said acute condition is selected from a group comprising renal toxicity and hepatotoxicity.

15

13. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use 20 in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the embodiments 8 to 12, wherein the binder is an anti-DPP3 antibody or anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold binding to an epitope according to SEQ ID NO.: 2, and wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said anti-DPP3 antibody or anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold exhibits a binding affinity to DPP3 of 25 at least 10^{-7} M.

25

14. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use 30 in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the embodiments 8 and 12, wherein said acute condition is hepatotoxicity which is drug-induced or alcohol-induced hepatotoxicity.

15. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to embodiment 5, wherein said acute condition is renal toxicity which is drug-induced renal toxicity.

16. The binder directed to and binding to an epitope according to SEQ ID NO.: 2 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the 10 embodiments 8 to 11, wherein said disease is associated with oxidative stress in the myocard.

17. Pharmaceutical composition comprising a binder according to any of the embodiments 1 to 7 for use in the prevention or treatment of a disease or acute condition of a patient, 15 whereby said disease or acute condition is associated with oxidative stress.

18. A kit comprising a binder according to any of the embodiments 1 to 16.

19. A binder directed to and binding to a DPP3 protein or functional derivative thereof for 20 use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress.

20. The binder for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to embodiment 19, wherein said diseases are selected from a group 25 comprising neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic shock and SIRS.

30 21. The binder for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the embodiments 19 or 20, and wherein said:

- neurodegenerative disease may be selected from a group comprising Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)),
- 5 ○ metabolic syndrome may be selected from a group comprising insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes,
- cardiovascular disorder may be selected from a group comprising atherosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction,
- 10 ○ autoimmune disease may be selected from a group comprising rheumatoid arthritis, systemic lupus erythematosus,
- inflammatory lung disease may be selected from a group comprising COPD, asthma,
- 15 ○ kidney disease may be selected from a group comprising acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD),
- liver disease may be selected from a group comprising viral hepatitis, and cirrhosis,
- 20 ○ digestive disease may be selected from a group comprising inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease, gastritis, pancreatitis and peptic ulcer,
- viral infectious disease may be selected from a group comprising blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus,
- 25 ○ cancer may be selected from a group comprising prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer,
- inflammation,
- sepsis, septic shock, SIRS.

30

22. A binder according to any of the embodiments 19 to 21, wherein said binder is directed to and binding to an epitope according to SEQ ID NO.: 2, and wherein said binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

23. The binder according any of the embodiments 19 to 22, wherein said binder is directed to and binding to an epitope according to SEQ ID NO.: 3, and wherein said binder recognizes and binds to at least three amino acids of SEQ ID NO.: 3.

5

24. The binder according to any of the embodiments 19 to 23, wherein said binder is directed to and binding to an epitope according to SEQ ID NO.: 4, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 4.

10

25. The binder according to any of the embodiments 19 to 24, wherein said binder is selected from a group comprising an antibody or antibody fragment or non-Ig scaffold.

15

26. The binder according to any of the embodiments 19 to 25, wherein said binder is a monoclonal antibody or monoclonal antibody fragment, and wherein the complementarity determining regions (CDR's) in the heavy chain comprises the sequences:

SEQ ID NO.: 7, SEQ ID NO.: 8 and/ or SEQ ID NO.: 9

20

and the complementarity determining regions in the light chain comprises the sequences:

SEQ ID NO.: 10, KVS and/ or SEQ ID NO.: 11.

25

27. The binder according any of the embodiments 19 to 26, wherein said binder is a humanized monoclonal antibody or humanized monoclonal antibody fragment, wherein the heavy chain comprises the sequence:

SEQ ID NO.: 12

30

and wherein the light chain comprises the sequence:

SEQ ID NO.: 13.

28. The binder according to any of the embodiments 19 to 27, wherein said binder is a dipeptidyl peptidase 3 (DPP3) binder directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three amino acids of SEQ ID NO.: 2.

Definitions

In accordance with the invention, an “DPP3 binder“ is directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three aa of SEQ ID NO.: 2 or a respective subsequence thereof according to the SEQ ID NO'S.: 3 or 4.

15 In accordance with the invention, a DPP3 binder is preferably an anti-DPP3 antibody, or an anti-DPP3 antibody fragment, or an anti-DPP3 non-Ig scaffold directed to and binding to an epitope according to SEQ ID NO.: 2, wherein said epitope is comprised in a DPP3 protein or a functional derivative thereof, and wherein said DPP3 binder recognizes and binds to at least three aa of SEQ ID NO.: 2 or a respective subsequence thereof according to the SEQ ID NO'S.: 3 or 4.

With the context of the invention, a “functional derivative” of a DPP3 protein denotes a peptide, polypeptide or protein that differs from the sequence of SEQ ID NO.: 1 by means of deletion of aa, addition of aa or changes of specific aa, but remains the bioactivity and function of a native DPP3 protein. Thereby, due to the modifications of the SEQ ID NO.: 1 the bioactivity and function may be influenced to a certain extent, but the enzymatic protease reaction catalysed by DDP 3 is still maintained when assay by a suitable bioactivity assay as described above or commonly known by the skilled person.

30 A person skilled in the art understands that a dipeptidyl peptidase 3 (DPP3) antibody or an anti-DPP3 antibody fragment or anti-DPP3 non-Ig scaffold is synonymous to dipeptidyl peptidase 3 (DPP3) antibody or a dipeptidyl peptidase 3 antibody fragment or DPP3 non-Ig scaffold and means anti- dipeptidyl peptidase 3 (DPP3) antibody or an anti- dipeptidyl peptidase 3 antibody fragment or anti-DPP3 non-Ig scaffold binding to DPP3, respectively.

Throughout the text, the term “antibody” generally comprises monoclonal and polyclonal antibodies and binding fragments thereof, in particular Fc-fragments as well as so called “single-chain-antibodies” (Bird et al. 1988), chimeric, humanized, in particular CDR-grafted antibodies, and di- or tetrabodies (Holliger et al. 1993). Also comprised are immunoglobulin-like proteins that are selected through techniques including, for example, phage display to specifically bind to the molecule of interest contained in a sample.

In this context the term “specific binding” refers to antibodies raised against the molecule of interest or a fragment thereof. An antibody is considered to be specific, if its affinity towards the molecule of interest or the aforementioned fragment thereof is at least preferably 50-fold higher, more preferably 100-fold higher, most preferably at least 1000-fold higher than towards other molecules comprised in a sample containing the molecule of interest. It is well known in the art how to make antibodies and to select antibodies with a given specificity.

15

“Diseases associated with oxidative stress” with the context of the present invention include, but are not limited to, neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, and inflammation, sepsis, septic shock, 20 SIRS.

In the context of the present invention, neurodegenerative diseases comprise Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS).

25

In the context of the present invention, metabolic syndrome comprises insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes.

30

In the context of the present invention, cardiovascular disorders comprise atherosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury/ stroke and myocardial infarction.

In the context of the present invention, autoimmune diseases comprise rheumatoid arthritis and systemic lupus erythematosus.

5 In the context of the present invention inflammatory lung diseases comprise COPD and asthma.

In the context of the present invention, kidney diseases comprise renal toxicity (drug-induced kidney disease), acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy and end-stage renal disease (ESRD).

10

In the context of the present invention, liver diseases comprise hepatotoxicity, viral hepatitis, cirrhosis.

15

In the context of the present invention, digestive diseases comprise inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease; gastritis, pancreatitis and peptic ulcer. In this context, viral infectious diseases comprise blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus and respiratory syncytial virus.

20

In the context of the present invention, cancer comprises prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer and liver cancer.

25

“Acute condition associated with oxidative stress” with the context of the present invention denote symptoms that appear and change or worsen rapidly due to the occurrence of oxidative stress. An acute condition associated with oxidative stress is sudden in onset. An acute condition associated with oxidative stress may lead to a chronic syndrome, if untreated.

30

By contrast, a “chronic condition” or a “chronic syndrome”, respectively, with the context of the present invention denote a condition or symptom that develops and worsens over an extended period of time, and may be persistent, even if treated.

“Oxidative stress” reflects an imbalance between the systemic manifestation of reactive oxygen species (ROS)/ reactive nitrogen species (RNS) and antioxidants in favour of excessive generation of free radicals. This process leads to the oxidation of biomolecules with consequent loss of its biological functions and/or homeostatic imbalances, whose 5 manifestation is the potential oxidative damage to cells and tissues. Accumulation of ROS/RNS can result in a number of deleterious effects such as lipid peroxidation, protein oxidation and DNA damage (including base damage and strand breaks). Further, some reactive oxidative species act as cellular messengers in redox signalling. Thus, oxidative stress can cause disruptions in normal mechanisms of cellular signalling.

10

A “free radical in the context of the present invention is a molecule with one or more unpaired electron in its outer shell. Free radicals are formed from molecules via the breakage of a chemical bond such that each fragment keeps one electron, by cleavage of a radical to give another radical and, also via redox reactions. Free radicals related to oxidative stress include 15 hydroxyl (OH[•]), superoxide (O₂^{•-}), nitric oxide (NO[•]), nitrogen dioxide (NO₂[•]), peroxy (ROO[•]) and lipid peroxy (LOO[•]). Also, hydrogen peroxide (H₂O₂), ozone (O₃), singlet oxygen (1O₂), hypochlorous acid (HOCl), nitrous acid (HNO₂), peroxynitrite (ONOO[•]), dinitrogen trioxide (N₂O₃), lipid peroxide (LOOH), are not free radicals and generally called oxidants, but can easily lead to free radical reactions in living organisms.

20

“Primary medicament” means a medicament that acts against the primary cause of said disease or condition.

“Secondary medication” is a medication that improves the condition of the patient in a 25 supportive way; e.g. reduces or regulates oxidative stress which is induced by the administration of a primary medicament.

With the context of the invention, generally the “bioactivity” is defined as the effect that a substance takes on a living organism or tissue or organ or functional unit *in vivo* or *in vitro* 30 (e.g. in an assay) after its interaction.

In this regard and specifically with the context of the invention, DPP3 bioactivity may be defined as the DPP3 enzyme activity or the regulating activity of DPP3 in the oxidative stress pathway.

ABBREVIATIONS

Abbreviation	Meaning
aa	amino acid(s)
AD	Alzheimer's disease
AHF	acute heart failure
AIN	Acute interstitial nephritis
AKI	acute kidney injury
ALD	Alcoholic liver disease
ALS	amyotrophic lateral sclerosis
ARE	antioxidant response element
ATN	Acute tubular necrosis
ATP	adenosine triphosphate
AZT	Azidothymidin
BRCA1	Breast cancer gene 1
BP	blood pressure
BSA	bovine serum albumin
cDNA	complementary DNA
CAT	catalase
CD	Celiac disease
CDR	complementarity determining region
CKD	chronic kidney disease
CLP	cecal ligation and puncture
CNS	central nervous system
COPD	Chronic obstructive pulmonary disease
CSF	Cerebrospinal fluid
CVD	cardiovascular diseases
DHE	dihydroethidium
DN	diabetic nephropathy

DNA	Deoxyribonucleic acid
DPP3, DPPIII	dipeptidyl dipeptidase 3
DTNB	(5,5'-dithiobis-(2-nitrobenzoic acid), Ellman's reagent
EBV	Eppstein Barr virus
EC	enzyme category
EDTA	Ethylene diamine tetraacetic acid
EF	ejection fraction
EOC	epithelial ovarian cancer
ESRD	end-stage renal disease
Fab	Fragment antigen binding
Fc	crystallisable fragment
FR	framework region
GC	Gastric cancer
GSH	glutathione
GPx	Glutathione peroxidase
HBV	Hepatitis B virus
HCV	Hepatitis C virus
HD	Huntington's disease
hDPP3	human DPP3
HF	heart failure
HFmrEF	heart failure with mid-range ejection fraction
HFpEF	heart failure with preserved ejection fraction
HFrEF	heart failure with reduced ejection fraction
HIV	human immunodeficiency virus
HNE	4-hydroxynonenal
IBD	Inflammatory bowel disease
i.p	intraperitoneally
i.v.	intravenous
Ig	immunoglobulin
KEAP1	Kelch like-ECH-associated protein 1
LV	left ventricular
LVEF	left ventricular ejection fraction

MDA	Malon dialdehyde
MS	multiple sclerosis
NAFLD	Non-alcoholic fatty liver disease
NHS	N-Hydroxysuccinimid
non-Ig	non-immunoglobulin
NOS	nitric oxide species
Nrf2	nuclear factor erythroid 2-related factor 2
NSAID	Non-steroidal anti-inflammatory drugs
o-	ortho
OS	Oxidative stress
PBS	phosphate buffered saline
PD	parkinson's disease
PEG	Polyethylene glycole
PEG	polyethylene glycole
pHMB	polyhexanide, polyhexamethylene biguanide
PMSF	phenylmethylsulfonyl fluoride
PUD	Peptic ulcer disease
RLU	relative light units
RNA	Ribonucleic acid
RNS	reactive nitrogen species
ROI	reactive oxygen intermediates
ROS	reactive oxygen species
RT	room temperature
scFv	single chain variable fragment
SDS	sodium dodecyl sulfate
SOB	shortness of breath
TPCK	tosyl phenylalanin chloromethyl ketone
TRX1	thioredoxin 1
TTE	transthoracic echocardiography
UV	ultraviolet
XNA	xeno nucleic acid

EXAMPLES

1. Example 1

5 Generation of antibodies and determination DPP3 binding ability: Several murine antibodies were produced and screened by their ability of binding human DPP3 in a specific binding assay (see table 3).

1.1. Methods:

- Peptides/ conjugates for immunization:

10 DPP3 peptides for immunization were synthesized, see table 3, (JPT Technologies, Berlin, Germany) with an additional N-terminal cystein (if no cystein is present within the selected DPP3-sequence) residue for conjugation of the peptides to Bovine Serum Albumin (BSA). The peptides were covalently linked to BSA by using Sulfolink-coupling gel (Perbio-science, Bonn, Germany). The coupling procedure was performed 15 according to the manual of Perbio. Recombinant GST-hDPP3 was produced by USBio (United States Biological, Salem, MA, USA).

- Immunization of mice, immune cell fusion and screening:

20 Balb/c mice were intraperitoneally (i.p.) injected with 84 µg GST-hDPP3 or 100 µg DPP3-peptide-BSA-conjugates at day 0 (emulsified in TiterMax Gold Adjuvant), 84 µg or 100 µg at day 14 (emulsified in complete Freund's adjuvant) and 42 µg or 50 µg at day 21 and 28 (in incomplete Freund's adjuvant). At day 49 the animal received an intravenous (i.v.) injection of 42 µg GST-hDPP3 or 50 µg DPP3-peptide-BSA-conjugates dissolved in saline. Three days later the mice were sacrificed 25 and the immune cell fusion was performed.

30 Splenocytes from the immunized mice and cells of the myeloma cell line SP2/0 were fused with 1 ml 50% polyethylene glycol for 30 s at 37°C. After washing, the cells were seeded in 96-well cell culture plates. Hybrid clones were selected by growing in HAT medium [RPMI 1640 culture medium supplemented with 20% fetal calf serum and HAT-Supplement]. After one week, the HAT medium was replaced with HT Medium for three passages followed by returning to the normal cell culture medium.

The cell culture supernatants were primarily screened for recombinant DPP3 binding IgG antibodies two weeks after fusion. Therefore, recombinant GST-tagged hDPP3 (USBiologicals, Salem, USA) was immobilized in 96-well plates (100 ng/ well) and incubated with 50 µl cell culture supernatant per well for 2 hours at room temperature. After washing of the plate, 50 µl / well POD-rabbit anti mouse IgG was added and incubated for 1 h at RT. After a next washing step, 50 µl of a chromogen solution (3,7 mM o-phenylenediamin in citrate/ hydrogen phosphate buffer, 0.012% H₂O₂) were added to each well, incubated for 15 minutes at RT and the chromogenic reaction stopped by the addition of 50 µl 4N sulfuric acid. Absorption was detected at 490 nm. The positive tested microcultures were transferred into 24-well plates for propagation. After retesting the selected cultures were cloned and recloned using the limiting-dilution technique and the isotypes were determined.

- **Mouse monoclonal antibody production**

Antibodies raised against GST-tagged human DPP3 or DPP3-peptides were produced via standard antibody production methods (Marx et al. 1997) and purified via Protein A. The antibody purities were ≥ 90% based on SDS gel electrophoresis analysis.

- **Characterization of antibodies – binding to hDPP3 and/ or immunization peptide**

To analyze the capability of DPP3/ immunization peptide binding by the different antibodies and antibody clones a binding assay was performed:

a) Solid phase

Recombinant GST-tagged hDPP3 (SEQ ID No. 1) or a DPP3 peptide (immunization peptide, SEQ ID No. 2) was immobilized onto a high binding microtiter plate surface (96-Well polystyrene microplates, Greiner Bio-One international AG, Austria, 1 µg/well in coupling buffer [50 mM Tris, 100 mM NaCl, pH7,8], 1h at RT). After blocking with 5% bovine serum albumin, the microplates were vacuum dried.

b) Labelling procedure (Tracer)

100 µg (100 µl) of the different antiDPP3 antibodies (detection antibody, 1 mg/ ml in PBS, pH 7.4) were mixed with 10 µl acridinium NHS-ester (1 mg/ml in

acetonitrile, InVent GmbH, Germany; EP 0 353 971) and incubated for 30 min at room temperature. Labelled antiDPP3 antibody was purified by gel-filtration HPLC on Shodex Protein 5 μ m KW-803 (Showa Denko, Japan). The purified labeled antibody was diluted in assay buffer (50 mmol/l potassium phosphate, 100 mmol/l NaCl, 10 mmol/l Na₂-EDTA, 5 g/l bovine serum albumin, 1 g/l murine IgG, 1 g/l bovine IgG, 50 μ mol/l amastatin, 100 μ mol/l leupeptin, pH 7.4). The final concentration was approx. 5-7*10⁶ relative light units (RLU) of labelled compound (approx. 20 ng labeled antibody) per 200 μ l. acridinium ester chemiluminescence was measured by using a Centro LB 960 luminometer (Berthold Technologies GmbH & Co. KG).

10 *c) hDPP3 binding assay*

The plates were filled with 200 μ l of labeled and diluted detection antibody (tracer) and incubated for 2-4 h at 2-8 °C. Unbound tracer was removed by washing 4 times 15 with 350 μ l washing solution (20 mM PBS, pH 7.4, 0.1 % Triton X-100). Well-bound chemiluminescence was measured by using the Centro LB 960 luminometer (Berthold Technologies GmbH & Co. KG).

20 **- Characterization of antibodies – hDPP3-inhibition analysis**

To analyze the capability of DPP3 inhibition by the different antibodies and antibody clones a DPP3 activity assay with known procedure (Jones et al., 1982) was performed. Recombinant GST-tagged hDPP3 was diluted in assay buffer (25 ng/ ml GST-DPP3 in 50 mM Tris-HCl, pH7,5 and 100 μ M ZnCl₂) and 200 μ l of this solution incubated with 10 μ g of the respective antibody at room temperature. After 1 hour of pre-incubation, 25 fluorogenic substrate Arg-Arg- β NA (20 μ l, 2mM) was added to the solution and the generation of free β NA over time was monitored using the Twinkle LB 970 microplate fluorometer (Berthold Technologies GmbH & Co. KG) at 37 °C. Fluorescence of β NA is detected by exciting at 340 nm and measuring emission at 410 nm. Slopes (in RFU/min) of increasing fluorescence of the different samples are calculated. The slope of GST-hDPP3 with buffer control is appointed as 100 % activity. The inhibitory ability of 30 a possible capture-binder is defined as the decrease of GST-hDPP3 activity by incubation with said capture-binder in percent.

1.2. Results:

The following table represents a selection of obtained antibodies and their binding rate in Relative Light Units (RLU) as well as their relative inhibitory ability (%; table 3). The monoclonal antibodies raised against the below depicted DPP3 regions, were selected by their ability to bind recombinant DPP3 and/ or immunization peptide, as well as by their inhibitory potential.

All antibodies raised against the GST-tagged, full length form of recombinant hDPP3 show a strong binding to immobilized GST-tagged hDPP3. Also antibodies raised against the SEQ ID 2 peptide bind to GST-hDPP3. The SEQ ID 2 antibodies also strongly bind to the immunization peptide. Those antibodies were characterized in more detail (see example 2). The monoclonal antibody AK1967, with the ability of inhibiting DPP3 activity by 70 %, was chosen as possible therapeutic antibody and was also used as template for chimerization and humanization.

15

Sequence number	Antigen/ Immunogen	hDPP3 region	Clone	hDPP3 binding [RLU]	immunization peptide binding [RLU]	Max. inhibition of hDPP3
SEQ ID: 1	GST tagged recombinant FL-hDPP3	1-737	2552	3.053.621	0	65%
			2553	3.777.985	0	35%
			2554	1.733.815	0	30%
			2555	3.805.363	0	25%
SEQ ID: 2	CETVINPETGEQIQSWYRSGE	474-493	1963	141.822	2.163.038	60%
			1964	100.802	2.041.928	60%
			1965	99.493	1.986.794	70%
			1966	118.097	1.990.702	65%
			1967	113.736	1.909.954	70%
			1968	105.696	2.017.731	65%
			1969	82.558	2.224.025	70%

Table 3: list of antibodies raised against full-length or sequences of hDPP3 and their ability to bind hDPP3 (SEQ ID No. 1) or immunization peptide (SEQ ID No. 2) in RLU, as well as the maximum inhibition of recombinant GST-hDPP3.

20 2. Example 2

Antibodies raised against SEQ ID NO. 2 were characterized in more detail (epitope mapping, binding affinities, specificity, inhibitory potential). Here the results for clone 1967 of SEQ ID NO. 2 ("AK1967") are shown as an example.

2.1. Methods:

- Determination of AK1967 epitope on DPP3:

5 For epitope mapping of AK1967 a number of N- or C-terminally biotinylated peptides were synthesized (peptides&elephants GmbH, Hennigsdorf, Germany). These peptides include the sequence of the full immunization peptide (SEQ ID No. 2) or fragments thereof, with stepwise removal of one amino acid from either C- or N-terminus (see table 5 for a complete list of peptides).

10 *a) Solid phase*

High binding 96 well plates were coated with 2 µg Avidin per well (Greiner Bio-One international AG, Austria) in coupling buffer (500 mM Tris-HCl, pH 7.8, 100 mM NaCl). Afterwards plate were washed and filled with specific solutions of biotinylated peptides (10 ng/ well; buffer – 1xPBS with 0.5% BSA)

15 *b) Labelling procedure (Tracer)*

AntiDPP3 antibody AK1967 was labelled with a chemiluminescence label according to Example 1.

20 *c) Peptide binding assay*

The plates were filled with 200 µl of labeled and diluted detection antibody (tracer) and incubated for 4 h at room temperature. Unbound tracer was removed by washing 4 times with 350 µl washing solution (20 mM PBS, pH 7.4, 0.1 % Triton X-100). Well-bound chemiluminescence was measured by using the Centro LB 960 luminometer (Berthold Technologies GmbH & Co. KG). Binding of AK1967 to the respective peptides is determined by evaluation of the relative light units (RLU). Any peptide that shows a significantly higher RLU signal than the unspecific binding of AK1967 is defined as AK1967 binder. The combinatorial analysis of binding and non-binding peptides reveals the specific DPP3 epitope of AK1967.

30 *- Determination of binding affinities using Octet:*

The experiment was performed using Octet Red96 (ForteBio). AK1967 was captured on kinetic grade anti-humanFc (AHC) biosensors. The loaded biosensors were then

dipped into a dilution series of recombinant GST-tagged human DPP3 (100, 33.3, 11.1, 3.7 nM). Association was observed for 120 seconds followed by 180 seconds of dissociation. The buffers used for the experiment are depicted in table 4. Kinetic analysis was performed using a 1:1 binding model and global fitting.

Buffer	Composition
Assay Buffer	PBS with 0.1% BSA, 0.02% Tween-21
Regeneration Buffer	10 mM Glycine buffer (pH 1.7)
Neutralization Buffer	PBS with 0.1% BSA, 0.02% Tween-21

5

Table 4: Buffers used for Octet measurements

- Western Blot analysis of Binding specificity of AK1967:

Blood cells from human EDTA-blood were washed (3x in PBS), diluted in PBS and lysed by repeated freeze-thaw-cycles. The blood cell lysate had a total protein concentration of 250 µg/ml, and a DPP3 concentration of 10 µg/ml. Dilutions of blood cell lysate (1:40, 1:80, 1:160 and 1:320) and of purified recombinant human His-DPP3 (31.25-500 ng/ml) were subjected to SDS-PAGE and Western Blot. The blots were incubated in 1.) blocking buffer (1xPBS-T with 5% skim milk powder), 2.) primary antibody solution (AK1967 1:2.000 in blocking buffer) and 3.) HRP labelled secondary antibody (goat anti mouse IgG, 1:1.000 in blocking buffer). Bound secondary antibody was detected using the Amersham ECL Western Blotting Detection Reagent and the Amersham Imager 600 UV (both from GE Healthcare).

- DPP3 inhibition assay:

To analyze the capability of DPP3 inhibition by AK1967 a DPP3 activity assay with known procedure (Jones et al., 1982) was performed. Recombinant GST-tagged hDPP3 was diluted in assay buffer (25 ng/ ml GST-DPP3 in 50 mM Tris-HCl, pH7,5) and increasing concentrations of AK1967 were added. Fluorogenic substrate Arg-Arg-βNA was added to the solution and the generation of free βNA over time was monitored using the Twinkle LB 970 microplate fluorometer (Berthold Technologies GmbH & Co. KG) at 37 °C. Fluorescence of βNA is detected by exciting at 340 nm and measuring emission at 410 nm. Slopes (in RFU/ min) of increasing fluorescence of the different samples are calculated. The slope of GST-hDPP3 with buffer control is appointed as 100 % activity. The inhibitory ability AK1967 is defined as the decrease of GST-hDPP3

activity by incubation with said antibody in percent. The resulting lowered DPP3 activities are shown in an inhibition curve in Figure 1C.

2.2. Results:

5 - Epitope mapping:

The analysis of peptides that AK1967 binds to and does not bind to revealed the DPP3 sequence INPETG (SEQ ID No. 3) as necessary epitope for AK1967 binding (see table 5).

peptide ID	peptide sequence														AK1967 binding		
#1	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	g	yes	
#2	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	t	g	yes
#3	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	t	g	yes
#4	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	t	g	yes
#5	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	t	g	yes
#6	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	t	g	yes
#7	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	t		no
#8	bio	a	f	n	f	d	q	e	t	v	i	n	p	e			no
#9	bio	a	f	n	f	d	q	e	t	v	i	n	p				no
#10	bio	a	f	n	f	d	q	e	t	v	i	n	p	e	t	g	no
#11																	no
#12																	no
#13																	no
#14																	yes
#15																	yes
#16																	yes
#17																	yes

Table 5: Peptides used for Epitope mapping of AK1967

10

- Binding affinity:

AK1967 binds with an affinity of 2.2×10^{-9} M to recombinant GST-hDPP3 (for more details see table 6 and for kinetic curves see Figure 1A).

KD (M)	kon(1/Ms)	kdis(1/s)	Full X^2	Full R^2
2.2E-09	1.6E+05	3.5E-04	0.0413	0.9987

15 Table 6: Kinetic Constants of AK1967 affinity measurements

- Specificity:

The only protein detected with AK1967 as primary antibody in lysate of blood cells was DPP3 at 80 kDa (Figure 1B). The total protein concentration of the lysate was

250 µg/ml whereas the estimated DPP3 concentration is about 10 µg/ml. Even though there is 25 times more unspecific protein in the lysate, AK1967 binds and detects specifically DPP3 and no other unspecific binding takes place.

5 - **Inhibitory potential:**

AK1967 inhibits 15 ng/ ml DPP3 in a specific DPP3 activity assay with an IC50 of about 15 ng/ml (Figure 1C).

3. **Example 3**

10 A septic shock model was used to induce heart failure in rats and then to characterize AK1967's influence on oxidative stress in myocardium.

3.1. **Methods:**

- **Study design**

15 The study flow is depicted in Figure 2 A below. After CLP or sham surgery the animals were allowed to rest for 20 hours with free access to water and food. Afterwards they were anesthetized, tracheotomy done and arterial and venous line laid. At 24 hours after CLP surgery either AK1967 or vehicle (saline) were administered with 2 mg/kg. As a safety measure hemodynamics were monitored 20 invasively and continuously from t = 0 till 3 h.

- **CLP model of septic shock**

25 Male Wistar rats (2-3 months, 300 to 400 g, group size refer to table 7) from the Centre d'élevage Janvier (France) were allocated randomly to one of three groups. All the animals were anesthetized using ketamine hydrochloride (90 mg/ kg) and xylazine (9 mg/ kg) intraperitoneally (i.p.). For induction of polymicrobial sepsis, cecal ligation and puncture (CLP) was performed using Rittirsch's protocol with minor modification. A ventral midline incision (1.5 cm) was made to allow exteriorization of the cecum. The cecum is then ligated just below the ileocecal valve and punctured once with an 18-gauge needle. The abdominal cavity is then closed in two layers, followed by fluid resuscitation (3 ml/ 100 g body of weight of saline injected subcutaneously) and returning the animal to its cage. Sham animals were subjected to 30 surgery, without getting their cecum punctured.

- **Experimentation time points and animal groups**

At t=0 (baseline) all CLP animals are in septic shock and developed a decrease in heart function (low blood pressure, low shortening fraction). At this time point 5 AK1967 (2 mg/kg) or vehicle (saline) were injected (i.v.) and saline infusion was started. There were 1 control group and 2 CLP groups which are summarized in the table below (table 7). At the end of the experiment, the animals were euthanized, and organs (e.g. heart) harvested for subsequent analysis.

Group	Group size	CLP	treatment
1 - sham	4	no	saline
2 - CLP-saline	5	yes	saline
3 - CLP-AK1967	5	yes	AK1967

Table 7: list of experimental groups

10

- **DHE labeling of ROS in myocardium**

Dihydroethidium (DHE; Sigma-Aldrich) staining was used to evaluate the in situ levels of superoxide anion in the myocardium. Cardiac cryostat sections (7 µm) of the ventricles were incubated with DHE (37 µM) for 30 min in a dark humidified chamber. Acquisition of fluorescent images of ethidium bromide with Leica fluorescence microscope was performed under identical setting whatever the block tissue. The stained area was measured with IPLab software and expressed as a percentage of area of interest (% of ROI).

20 **3.2. Results:**

Rats with septic shock induced heart failure after CLP surgery develop high amounts of reactive oxygen species (ROS) in their myocardium, whereas sham operated animals show almost no oxidative stress (Figures 2 B and C). Treatment of the sick (CLP) animals with AK1967 reduces the oxidative stress levels in the myocardium to levels of 25 healthy (sham-operated) animals. This strong ROS decrease is achieved within only 3 hours of treatment (Figures 2 B and C).

REFERENCES

Abramić, M. et al., 2000. Human and rat dipeptidyl peptidase III: Biochemical and mass spectrometric arguments for similarities and differences. *Biological Chemistry*, 381(December), pp.1233–1243.

Abramić, M., Zubanović, M. & Vitale, L., 1988. Dipeptidyl peptidase III from human erythrocytes. *Biol Chem Hoppe Seyler*, pp.29–38.

Adamczyk B. et al. 2016. New Insights into the Role of Oxidative Stress Mechanisms in the Pathophysiology and Treatment of Multiple Sclerosis. *Oxidative Medicine and Cellular Longevity*, Vol. 2016, pp. 1-18, DOI: 10.1155/2016/1973834"

Agić, D. et al., 2007. Novel amidino-substituted benzimidazoles: Synthesis of compounds and inhibition of dipeptidyl peptidase III. *Bioorganic Chemistry*, 35(2), pp.153–169.

Almagro JC, Fransson J., 2008. Humanization of antibodies. *Front Biosci.* 2008 Jan 1;13:1619-33.

Aoyagi, T. et al., 1993. Enzymatic Changes in Cerebrospinal Fluid of Patients with Alzheimer-Type Dementia. *J Clin Biochem Nutr*, 14, pp.133–139.

Balogun, R.A. et al., 2010. Clinical applications of therapeutic apheresis. *Journal of clinical apheresis*, 25(5), pp.250–64.

Baršun, M. et al., 2007. Human dipeptidyl peptidase III acts as a post-proline-cleaving enzyme on endomorphins. *Biological Chemistry*, 388(3), pp.343–348.

Bhattacharyya A. et al. 2014. Oxidative stress: An essential factor in pathogenesis of gastrointestinal mucosal diseases. *Physiol Rev.* 94, pp. 329–354.

Bird et al., 1988. Single-chain antigen-binding proteins. *Science* 242:423-426.

Chen H. et al. 2011. Oxidative Stress in Ischemic Brain Damage: Mechanisms of Cell Death and Potential Molecular Targets for Neuroprotection. *Antioxidants and redox signaling*, 14, pp. 1505-1517.

Chen, W. et al., 2009. Direct interaction between Nrf2 and p21Cip1/WAF1 upregulates the Nrf2-mediated antioxidant response. *Mol Cell.*, 34(6), pp. 663-673.

Chiba, T. et al., 2003. Inhibition of recombinant dipeptidyl peptidase III by synthetic hemorphin-like peptides. *Peptides*, 24(5), pp.773–778.

Couston, R.G. et al., Adsorption behavior of a human monoclonal antibody at hydrophilic and hydrophobic surfaces. *mAbs*, 5(1), pp.126–39.

Deavall, D. G. et al., 2012. Drug-induced oxidative stress and toxicity. *J Toxicol*, pp. 645460.

Deng, B. et al., 2014. Aptamer binding assays for proteins: The thrombin example-A review. *Analytica Chimica Acta*, 837, pp.1–15.

Dhanda, S., Singh, J. & Singh, H., 2008. Hydrolysis of various bioactive peptides by goat brain dipeptidylpeptidase-III homologue. *Cell biochemistry and function*, 26(3), pp.339–45.

Elahi M. M. et al. 2009. Oxidative stress as a mediator of cardiovascular disease. *Oxidative Medicine and Cellular Longevity*, 2:5, pp. 259-269.

Ellis, S. & Nuenke, J.M., 1967. Dipeptidyl Arylamidase III of the Pituitary: Purification and Characterization. *Journal of Biological Chemistry*, 242(20), pp.4623–4629.

Gamrekelashvili, J. et al., 2013. Peptidases released by necrotic cells control CD8 + T cell cross-priming. *Journal of clinical investigation*, 123(11), pp.4755–4768.

Hartley et al, 1982. *Radiology* 143: 29-36

Hast B. E. et al., 2013. Proteomic analysis of ubiquitin ligase KEAP1 reveals associated proteins that inhibit NRF2 ubiquitination. *Cancer Res.*, 73(7), pp. 2199-2210.

Hast B. E. et al., 2014. Cancer-Derived Mutations in KEAP1 Impair NRF2 Degradation but not Ubiquitination. *Molecular and Cellular Pathobiology*. *Cancer research*, 74 (3), pp. 808-817.

Holguin F. 2013. Oxidative Stress in Airway Diseases. *Ann. Am. Thorac. Soc.*, Vol 10, Supplement, pp. S150–S157.

Holliger P. et al. (1993) *Proc. Natl. Acad. Sci. U.S.A.* 90:6444-8

Hood et al., *Immunology*, Benjamin, N.Y., 2nd ed., 1984

Hori M. et al. 2009, Oxidative stress and left ventricular remodelling after myocardial infarction. *Cardiovascular research*, 81, pp. 457-464.

Hosohata K. 2016. Role of Oxidative Stress in Drug-Induced Kidney Injury. *International Journal of Molecular Sciences*, 17, pp. 1826-1836.

Hultschig C et al., *Curr Opin Chem Biol*. 2006 February; 10(1):4-10. PMID: 16376134)

Hunkapiller & Hood, 1986. The growing immunoglobulin gene superfamily. *Nature* 323:15-16.

Hust, M., Meyer, T., Voedisch, B., Rülker, T., Thie, H., El-Ghezal, A., Kirsch, M.I., Schütte, M., Helmsing, S., Meier, D., Schirrmann, T., Dübel, S., 2011. A human scFv antibody generation pipeline for proteome research. *Journal of Biotechnology* 152, 159–170

Huston et al., 1988. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.*, 85:5879-5883.

5 Hutcheson R. et al. The Metabolic Syndrome, Oxidative Stress, Environment, and Cardiovascular Disease: The Great Exploration. *Experimental Diabetes Research*, Vol. 2012, Article ID 271028.

Igic, R. & Behnia, R., 2007. Pharmacological, immunological, and gene targeting of the renin-angiotensin system for treatment of cardiovascular disease. *Current pharmaceutical design*, 13(12), pp.1199–214.

10 Inaoka, Y. & Naruto, S., 1988. Propioxatins A and B, New Enkephalinase B Inhibitors, IV. Characterization of the Active Site of the Enzyme Using Synthetic Propioxatin Analogues. *J. Biochem*, 104(5), pp.706–711.

Ivanov A. V. et al. 2017. Oxidative Stress in Infection and Consequent Disease. *Oxidative Medicine and Cellular Longevity*, Vol. 2017, Article ID 3496043.

15 Ivanov A. V. et al. 2017. Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis. *Oncotarget*, 8, pp. 3895-3932.

Jones, T.H. & Kapralou, A, 1982. A rapid assay for dipeptidyl aminopeptidase III in human erythrocytes. *Analytical biochemistry*, 119(2), pp.418–23.

20 Kabat et al., 1983. Sequences of Proteins of Immunological Interest, U.S. Department of Health and Human Services.

Kaymak C. et al. 2011. Reactive Oxygen Species (Ros) Generation in Sepsis. *FABAD J. Pharm. Sci.*, 36, pp. 41-47.

Khaket, T.P. et al., 2012. Enkephalin degrading enzymes: metalloproteases with high potential for drug development. *Current pharmaceutical design*, 18(2), pp.220–30.

25 Khandrika L. et al. 2009. Role of Oxidative Stress in Prostate Cancer. *Cancer Lett.*, 282(2), pp. 125–136.

Kim, D. & Herr, A.E., 2013. Protein immobilization techniques for microfluidic assays. *Biomicrofluidics*, 7(4), p.41501.Kirk-Othmer, *Encyclopedia of chemical technology*, 4th ed., executive editor, J. I. Kroschwitz; editor, M. Howe-Grant, John Wiley & Sons, 1993, vol. 15, p. 518-562

Kruk J. et al. 2017. Reactive Oxygen and Nitrogen Species in Carcinogenesis: Implications of Oxidative Stress on the Progression and Development of Several Cancer Types. *Mini-Reviews in Medicinal Chemistry*, 17, pp. 904-919.

5 Kumar, P. et al., 2016. Substrate complexes of human dipeptidyl peptidase III reveal the mechanism of enzyme inhibition. *Scientific Reports*, 6(March), p.23787.

Lanzavecchia, A. & Scheidegger, D., 1987. The use of hybrid hybridomas to target human cytotoxic T lymphocytes, *Eur. J. Immunol.* 17:105.

10 Lee, C.M. & Snyder, S.H., 1982. Dipeptidyl-aminopeptidase III of rat brain. Selective affinity for enkephalin and angiotensin. *The Journal of biological chemistry*, 257(20), pp.12043–50.

Li S. et al. 2015. The Role of Oxidative Stress and Antioxidants in Liver Diseases. *International Journal of Molecular Sciences*, 16, pp. 26087-26124.

Li, J. et al., 2011. Peptide aptamers with biological and therapeutic applications. *Current medicinal chemistry*, 18(27), pp.4215–22.

15 Liu Z. et al. 2017. Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications. *Oxidative Medicine and Cellular Longevity*, Vol. 2017, Article ID 2525967.

Liu, Y. et al., 2007. A genomic screen for activators of the antioxidant response element. *Proceedings of the National Academy of Sciences of the United States of 20 America*, 104(12), pp.5205–10.

Lu K. et al., 2017. NRF2 induction supporting breast cancer cell survival is enabled by oxidative stress-induced DPP3-KEAP2 interaction. *OnlineFirst*; DOI: 10.1158/0008-5472.CAN-16-2204.

25 Ma Q. et al., Role of Nrf2 in Oxidative Stress and Toxicity. *Annu Rev Pharmacol Toxicol.*, 53, pp. 401-426.

Ma Y. et al. 2013, Relation between Gastric Cancer and Protein Oxidation, DNA Damage, and Lipid Peroxidation. *Oxidative Medicine and Cellular Longevity*, Vol. 2013, Article ID 543760.

Marx et al., 1997. Monoclonal Antibody Production, *ATLA* 25, 121.

30 Mazzocco, C. et al., 2006. Identification and characterization of two dipeptidyl-peptidase III isoforms in *Drosophila melanogaster*. *FEBS Journal*, 273(5), pp.1056–1064.

Meliopoulos, V.A. et al., 2012. MicroRNA regulation of human protease genes essential for influenza virus replication. *PloS one*, 7(5), p.e37169.

Müller, J. et al., 2012. Monitoring of plasma levels of activated protein C using a clinically applicable oligonucleotide-based enzyme capture assay. *Journal of Thrombosis and Haemostasis*, 10(3), pp.390–398.

5 Müller, J. et al., 2016. Aptamer-Based Enzyme Capture Assay for Measurement of Plasma Thrombin Levels. *Methods in molecular biology* (Clifton, N.J.), 1380, pp.179–89.

Narendhirakannan R. T. et al., 2012. Oxidative Stress and Skin Cancer: An Overview. *Ind. J. Clin. Biochem.*, 28, pp. 110–115.

10 Nourazarian A. R. et al., 2014. Roles of Oxidative Stress in the Development and Progression of Breast Cancer. *Asian Pac. J. Cancer Prev.*, 15 (12), pp. 4745-4751

Ohkubo, I. et al., 1999. Dipeptidyl peptidase III from rat liver cytosol: purification, molecular cloning and immunohistochemical localization. *Biological chemistry*, 380(12), pp.1421–1430.

15 Patel, A., Smith, H.J. & Sewell, R.D., 1993. Inhibitors of enkephalin-degrading enzymes as potential therapeutic agents. *Progress in medicinal chemistry*, 30, pp.327–78.

Perl A. 2013. Oxidative stress in the pathology and treatment of systemic lupus erythematosus. *Nat. Rev. Rheumatol.*, 9(11), pp. 674–686.

20 Perse M., 2013. Oxidative Stress in the Pathogenesis of Colorectal Cancer: Cause or Consequence?. *BioMed Research International*, Vol. 2013, Article ID 725710.

Pham-Huy et al. 2008. Free Radicals, Antioxidants in Disease and Health. *Int. J. Biomed. Sci.*, 4 (2), pp. 89-96.

25 Pinheiro Da Silva, F. & Nizet, V., 2009. Cell death during sepsis: Integration of disintegration in the inflammatory response to overwhelming infection. *Apoptosis*, 14(4), pp.509–521.

Pitocco et al. 2013. Oxidative Stress in Diabetes: Implications for Vascular and Other Complications. *Int. J. Mol. Sci.*, 14, pp. 21525-21550.

30 Pohanka M. 2013. Role of oxidative stress in infectious diseases. A review. *Folia Microbiol.*, 58, pp. 503–513.

Prajapati, S.C. & Chauhan, S.S., 2011. Dipeptidyl peptidase III: a multifaceted oligopeptide N-end cutter. *FEBS Journal*, 278(18), pp.3256–3276.

Quiñonez-Flores C. M. 2016, Oxidative Stress Relevance in the Pathogenesis of the Rheumatoid Arthritis: A Systematic Review. *BioMed Research International* Volume 2016, Article ID 6097417.

Raghupathi, R., 2004. Cell death mechanisms following traumatic brain injury. *Brain pathology* (Zurich, Switzerland), 14(2), pp.215–22.

Rastija, V. et al., 2015. Synthesis, QSAR, and Molecular Dynamics Simulation of Amidino-substituted Benzimidazoles as Dipeptidyl Peptidase III Inhibitors. *Acta Chimica Slovenica*, 62, pp.867–878.

Rittirsch, D., Huber-Lang, M., Flierl, M. Ward, P.: Immunodesign of experimental sepsis by cecal ligation and puncture, *Nature Protocols* 4, - 31 - 36 (2009)

Rodrigo R. et al., 2013. Oxidative Stress and Pathophysiology of Ischemic Stroke: Novel Therapeutic Opportunities. *CNS & Neurological Disorders - Drug Targets*, DOI: 10.2174/1871527311312050015.

Romanillos, G. et al. EP 2949332 A2

Saed G. M. et al., 2017. Updates of the role of oxidative stress in the pathogenesis of ovarian cancer. *Gynecologic Oncology*, 145, pp. 595–602.

Sanderink, G.J., Artur, Y. & Siest, G., 1988. Human aminopeptidases: a review of the literature. *Journal of clinical chemistry and clinical biochemistry*. *Zeitschrift für klinische Chemie und klinische Biochemie*, 26(12), pp.795–807.

Sawicka E. et al. 2015. The role of oxidative stress in bladder cancer, *Postepy Hig Med Dosw*, 69, pp. 744-752.

Schütte, M., Thullier, P., Pelat, T., Wezler, X., Rosenstock, P., Hinz, D., Kirsch, M.I., Hasenberg, M., Frank, R., Schirrmann, T., Gunzer, M., Hust, M., Dübel, S., 2009. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of *Aspergillus fumigatus*. *PLoS One* 4, e6625

Schwarz K. B. 1996, Oxidative stress during viral infection. *Free Radical Biology & Medicine*, 21, No. 5, pp. 641-649.

Shimamori, Y., Watanabe, Y. & Fujimoto, Y., 1986. Purification and Characterization of Dipeptidyl Aminopeptidase III from Human Placenta. *Chem. Pharm. Bull.*, 34(8), pp.3333–3340.

Šimaga, Š. et al., 1998. Dipeptidyl peptidase III in malignant and non-malignant gynaecological tissue. *European Journal of Cancer*, 34(3), pp.399–405.

Šimaga, Š. et al., 2003. Tumor cytosol dipeptidyl peptidase III activity is increased with histological aggressiveness of ovarian primary carcinomas. *Gynecologic Oncology*, 91(1), pp.194–200.

Singh, R. et al., 2014. Transcription factor C/EBP-beta mediates downregulation of dipeptidyl-peptidase III expression by interleukin-6 in human glioblastoma cells. *FEBS Journal*, 281, pp.1629–1641.

Sobocanec et al., 2015. The role of 17 β -estradiol in the regulation of antioxidant enzymes via the Nrf2-Keap1 pathway in the livers of CBA/H mice. *Life Sciences*, 130, pp. 57-65

Sobocanec et al., 2016. Prominent role of exopeptidase DPP III in estrogen-mediated protection against hyperoxia in vivo. *Redox Biology*, 8, pp. 49-159

Sosa et al. 2013. Oxidative stress and cancer: An overview. *Ageing Research Reviews*, 12, pp. 376– 390.

Sureshbabu A. 2015. Oxidative stress and autophagy: Crucial modulators of kidney injury. *Redox Biology*, 4, pp. 208–214.

Tian T. et al. 2017. Pathomechanisms of Oxidative Stress in Inflammatory Bowel Disease and Potential Antioxidant Therapies. *Oxidative Medicine and Cellular Longevity*, Vol. 2017, Article ID 4535194.

Ullah A. et al. 2015. Diabetes mellitus and oxidative stress—A concise review. *Saudi Pharmaceutical Journal*, 24, pp. 547–553.

Vairappan B. 2015. Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress. *World Journal of Hepatology*, 7 (3), pp. 443-459.

Valavanidis A. et al. 2013, Pulmonary Oxidative Stress, Inflammation and Cancer: Respirable Particulate Matter, Fibrous Dusts and Ozone as Major Causes of Lung Carcinogenesis through Reactive Oxygen Species Mechanisms. *Int. J. Environ. Res. Public Health*, 10, pp. 3886-3907.

Vandenberg, I., King, F. & Kuchel, P., 1985. Enkephalin Degradation by Human Erythrocytes and Hemolysates Studied Using ^1H NMR Spectroscopy. *Archives of Biochemistry and Biophysics*, 242(2), pp.515–522.

Vanha-Perttula, T., 1988. Dipeptidyl peptidase III and alanyl aminopeptidase in the human seminal plasma: origin and biochemical properties. *Clinica chimica acta; international journal of clinical chemistry*, 177(2), pp.179–95.

Volonte, D. et al., 2013. Inhibition of nuclear factor-erythroid 2-related factor (Nrf2) by caveolin-2 promotes stress-induced premature senescence. *Molecular Biology of the Cell*, 24, pp. 1852-1862.

Wang Z. et al., 2016. Oxidative Stress and Liver Cancer: Etiology and Therapeutic Targets. *Oxidative Medicine and Cellular Longevity*, Vol. 2016, Article ID: 7891574.

Wattiaux, R. et al., 2007. Lysosomes and Fas-mediated liver cell death. *The Biochemical journal*, 403(1), pp.89–95.

5 Wild, David (2005). *The Immunoassay Handbook*, Elsevier LTD, Oxford; 3rd ed., ISBN-13: 978-0080445267

Xu, Y., Yang, X. & Wang, E., 2010. Review: Aptamers in microfluidic chips. *Analytica chimica acta*, 683(1), pp.12–20.

Yamamoto, Y. et al., 1998. Inhibitory action of spinorphin, an endogenous regulator of enkephalin-degrading enzymes, on carrageenan-induced polymorphonuclear neutrophil accumulation in mouse air-pouches. *Life sciences*, 62(19), pp.1767–73.

10 Yamamoto, Y. et al., 2000. Characterization of tynorphin, a potent endogenous inhibitor of dipeptidyl peptidaseIII. *Peptides*, 21(4), pp.503–8.

15 Zong, W.-X. & Thompson, C.B., 2006. Necrotic Cell Death as a Cell Fate. *Genes & Development*, 20, pp.1–5.

Zuk et al., Enzyme Immunoassay--A Quantitative Immunoassay Requiring No Instrumentation, *Clinical Chemistry*, 31 (7): 1144-1150 (1985)

SEQUENCE LISTING

SEQ ID No. 1 – hDPP3 aa 1-737

MADTQYILPNDIGVSSLDCREAFRLSPTERLYAYHLSRAAWYGGAVLLQTSPEAP
 5 YIYALLSRLFRAQDPDQLRQHALAEGLTEEEYQAFLVYAAGVYSNMGNYKSGD
 FVPNLPKEKLERVILGSEAAQQHPEEVRLWQTCGELMFSLEPRLRHLGLGKEG
 FSGNCTMEDAKLAQDFLDSQNLSAYNTRLFKEVDGEGKPYYEVRLASVLGSEPSL
 DS EVTSKLKSYEFRGSPFQVTRGDYAPILQKVVEQLEKAKAYAANSHQGQMLAQYIES
 TQGSIEAHKRGSRFWIQDKGPIVESYIGFIESYRDPFGSRGEFEGFVAVVNKAMSAK
 10 RLVASAEQLLKELPWPPTEKDKFLTPDFTSLDVLTFAGSGIPAGINIPNYDDL
 RQTEG FKNVSLGNVLAVAYATQREKLTLEEDDKDLYILWKGPSFDVQVGLHELLGH
 GSGK LFVQDEKGAFNFDQETVINPETGEQIQSWYRSGETWDSKFSTIASSYEECRA
 ESVGLY LCLHPQVLEIFGFEGADAEDVIYVNWLNMVRAGLLALEFYTPEAFNWR
 RQAHMQARF VILRVLLEAGEGLVTITPTTGS DGRPDARVRLDRSKIRSVG
 KPALERFLRRLQVLKSTG 15 DVAGGRALYEGYATVTDAPPECFLRLDTVLLR
 KESRKLI VQPNT RLEGSDVQLLEY EASAAGLIRSF SERFPEDGPE
 LEEILTQLATADARFWKG PSEAPSGQA

SEQ ID No. 2 – hDPP3 aa 474-493 (N-Cys) – immunization peptide with additional N-terminal Cystein

20 CETVINPETGEQIQSWYRSGE

SEQ ID No. 3 – hDPP3 aa 477-482 – epitope of AK1967

INPETG

25 **SEQ ID No. 4 – hDPP3 aa 480-483**

ETGE

SEQ ID No. 5 – variable region of murine AK1967 in heavy chain

QVTLKESGPGILQPSQLSLTCSFGFSLSTGMSVGWIRQPSGKGLEWLAHIWWNDN
 30 KSYNPALKSRLTISRDT SNNQVFLKIASVVTADTGTYFCARNYSYDYWGQGTT
 LTV S

SEQ ID No. 6 – variable region of murine AK1967 in light chain

DVVVTQTPLSLSVSLGDPASISCRSSRSLVHSIGSTYLYHWYLQKPGQSPKLLIYKVSNR
 FSGVPDRFSGSGSGTDFTLKISRVEAEDLGVYFCSQSTHVPWTFGGGTKLEIK

5 **SEQ ID No. 7 – CDR1 of murine AK1967 in heavy chain**

GFSLSTSGMS

SEQ ID No. 8 – CDR2 of murine AK1967 in heavy chain

IWWNDNK

10

SEQ ID No. 9 – CDR 3 of murine AK1967 in heavy chain

ARNYSYDY

SEQ ID No. 10 – CDR1 of murine AK1967 in light chain

15 RSLVHSIGSTY

CDR2 of murine AK1967 in light chain

KVS

20 **SEQ ID No. 11 - CDR3 of murine AK1967 in light chain**

SQSTHVPWT

SEQ ID No. 12 – humanized AK1967 – heavy chain sequence (IgG1κ backbone)

MDPKGSLSWRILLFLSLAFELSYGQITLKESGPTLVKPTQTLTCTFSGFSLSTSGMS
 25 VGWIRQPPGKALEWLAHIWWNDNKSYNPALKSRLTITRDTSKNQVVLMTNMDPV
 DTGTYYCARNYSYDYWGQGTLTVSSASTKGPSVPLAPSSKSTSGGTAALGCLVK
 DYFPEPVTVSWNSGALTSGVHTFPALQSSGLYSLSSVTVPSQLGTQTYICNVNHK
 PSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVV
 VDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKE
 30 YKCKVSNKALPAPIEKTIASKAKGQPREPVYTLPPSRDELTKNQVSLTCLVKGFYPSDI
 AVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH
 NHYTQKSLSLSPG

SEQ ID No. 13 – humanized AK1967 – light chain sequence (IgG1κ backbone)

METDTLLWVLLLWVPGSTGDIVMTQTPLSLSVTPGQPASISCKSSRSLVHSIGSTYLY

WYLQKPGQSPQLIYKVSNRFSGVPDFSGSGSGTDFTLKISRVEAEDGVVYYCSQST

HVPWTFGGKTKEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLNNFYPREAKVQWK

5 VDNALQSGNSQESVTEQDSKDSTYSLSSLTLSKADYEHKVYACEVTHQGLSSPVT
KSFNRGEC

FIGURE DESCRIPTION

Fig. 1: AK1967 characterization

5 (A) Association- and dissociation curve of the AK1967-DPP3 binding analysis using Octet. AK1967 loaded biosensors were dipped into a dilution series of recombinant GST-tagged human DPP3 (100, 33.3, 11.1, 3.7 nM) and association and dissociation monitored.

10 (B) Western Blot of dilutions of blood cell lysate and detection of DPP3 with AK1967 as primary antibody.

15 (C) Inhibition curve of native DPP3 from blood cells with inhibitory antibody AK1967. Inhibition of DPP3 by a specific antibody is concentration dependent, with an IC_{50} at ~ 15 ng/ml when analyzed against 15 ng/ml DPP3.

Fig. 2: Influence of AK1967 on oxidative stress in rats with septic shock induced heart failure

20 (A) Experimental design of heart failure study of rats in septic shock.

(B) Fluorescence images of DHE labelled myocardium of sham, CLP and CLP AK1967 animals.

25 (C) Quantification of DHE stained areas and expression as percentage of area of interest (% of ROI).

AMENDED CLAIMS

received by the International Bureau on 19 July 2019 (19.07.2019)

5 1. A dipeptidyl peptidase 3 (DPP3) binder directed to and binding to an epitope according to SEQ ID NO.: 2, and wherein said DPP3 binder recognizes and binds to at least three amino acids, particularly to at least four amino acids, more particularly to at least five amino acids of SEQ ID NO.: 2, wherein said epitope is comprised in SEQ ID NO.: 1, and wherein said DPP3 binder exhibit an affinity towards DPP3 in such that the affinity constant is at least 10^7 M⁻¹.

10 2. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of claim 1, wherein said DPP3 binder is directed to and binding to an epitope according to SEQ ID NO.: 3, and wherein said DPP3 binder recognizes and binds to at least three amino acids, particularly to at least four amino acids, more particularly to at least five amino acids of SEQ ID NO.: 3.

15 3. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of claim 1 or claim 2, wherein said DPP3 binder is directed to and binding to an epitope according to SEQ ID NO.: 4, and wherein said DPP3 binder recognizes and binds to at least three amino acids, particularly to the four amino acids of SEQ ID NO.: 4.

20 4. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the claims 1 to 3, wherein said DPP3 binder is selected from a group comprising an antibody or antibody fragment or non-Ig scaffold.

25 5. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the claims 1 to 4, wherein said DPP3 binder is selected from a group comprising a monospecific antibody or a monospecific antibody fragment or a monospecific non-Ig scaffold.

30 6. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding claims, wherein said DPP3 binder is a

monoclonal antibody or monoclonal antibody fragment, and wherein the complementarity determining regions (CDR's) in the heavy chain comprises the sequences:

5 SEQ ID NO.: 7, SEQ ID NO.: 8 and/ or SEQ ID NO.: 9

and the complementarity determining regions (CDR's) in the light chain comprises the sequences:

10 SEQ ID NO.: 10, KVS and/or SEQ ID NO.: 11.

7. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding claims, wherein said DPP3 binder is a humanized monoclonal antibody or humanized monoclonal antibody fragment, wherein the heavy chain comprises the sequence:

15 SEQ ID NO.: 12

and wherein the light chain comprises the sequence:

20 SEQ ID NO.: 13.

25 8. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 of any of the preceding claims for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress.

30 9. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to claim 7, wherein said diseases are selected from a group comprising neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases,

inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic shock and SIRS.

10. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to claim 7 or 8, and wherein said:

- 10
 - neurodegenerative disease may be selected from a group comprising Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)),
 - metabolic syndrome may be selected from a group comprising insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes,
 - cardiovascular disorder may be selected from a group comprising atherosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction,
 - autoimmune disease may be selected from a group comprising rheumatoid arthritis, systemic lupus erythematosus,
 - inflammatory lung disease may be selected from a group comprising COPD, asthma,
 - kidney disease may be selected from a group comprising acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD),
 - liver disease may be selected from a group comprising viral hepatitis, and cirrhosis,
 - digestive disease may be selected from a group comprising inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease, gastritis, pancreatitis and peptic ulcer,
 - viral infectious disease may be selected from a group comprising blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus,

- cancer may be selected from a group comprising prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer,
- inflammation,
- sepsis, septic shock, SIRS.

5

11. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the claims 7 to 9, wherein said disease is selected from a group comprising sepsis, septic shock, and SIRS.

10

12. The dipeptidyl peptidase 3 binder directed to and binding to an epitope according to SEQ ID NO.: 2 as defined in any of the preceding claims 1 to 6 for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the claims 7 to 9, wherein said disease is associated with oxidative stress in the myocard.

15

20

13. A dipeptidyl peptidase 3 binder directed to and binding to a DPP3 protein or functional derivative thereof for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress.


25

30

14. The dipeptidyl peptidase 3 binder for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to claim 13, wherein said diseases are selected from a group comprising neurodegenerative diseases, metabolic syndrome, cardiovascular disorders, autoimmune diseases, inflammatory lung diseases, kidney diseases, liver diseases, digestive diseases, viral infectious diseases, cancer, inflammation, sepsis, septic shock and SIRS.

15. The dipeptidyl peptidase 3 binder for use in the prevention or treatment of diseases or acute conditions in a patient, wherein said disease or acute condition is associated with oxidative stress according to any of the claims 13 or 14, and wherein said:

- 5 ○ neurodegenerative disease may be selected from a group comprising Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS)),
- 10 ○ metabolic syndrome may be selected from a group comprising insulin resistance, obesity, hyperglycemia, dyslipidemia, hypertension and diabetes,
- 15 ○ cardiovascular disorder may be selected from a group comprising atherosclerosis, hypertension, heart failure, cardiovascular ischemia, cerebral ischemic injury, stroke and myocardial infarction,
- 20 ○ autoimmune disease may be selected from a group comprising rheumatoid arthritis, systemic lupus erythematosus,
- 25 ○ inflammatory lung disease may be selected from a group comprising COPD, asthma,
- 30 ○ kidney disease may be selected from a group comprising acute kidney injury (AKI), chronic kidney disease (CKD), diabetic nephropathy, end-stage renal disease (ESRD),
- liver disease may be selected from a group comprising viral hepatitis, and cirrhosis,
- digestive disease may be selected from a group comprising inflammatory bowel disease e.g. Ulcerative colitis, Crohn's disease, gastritis, pancreatitis and peptic ulcer,
- viral infectious disease may be selected from a group comprising blood-borne hepatitis viruses (B, C, and D), human immunodeficiency virus (HIV), influenza A, Epstein-Barr virus, respiratory syncytial virus,
- cancer may be selected from a group comprising prostate cancer, breast cancer, lung cancer, colorectal cancer, bladder cancer, ovarian cancer, skin cancer, stomach cancer, liver cancer,
- inflammation,
- sepsis, septic shock, SIRS.

FIGURES**Fig. 1 A:**

5




Fig. 1 B:

Fig. 1 C:



15

Fig. 2 A:



20 mAbDPP3 = murine anti-DPP3 antibody


Fig. 2 B:

Fig. 2 C: